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ABSTRACT 
Type I collagen, the most abundant protein in the human body, is the primary organic 
component of bone and forms fibrils with a periodic spacing (D-spacing) along the fibril axis. 
These collagen fibrils are organized into larger hierarchical structures. Using atomic force 
microscopy (AFM), individual microfibrils were quantitatively characterized and a minimum of 
90 collagen molecules were required before D-spacing was observed. The arrangement of type I 
collagen fibrils into microstructures in bone tissue altered upon estrogen depletion, a model for 
postmenopausal osteoporosis, as well as drug treatments for osteoporosis. 
 Micro-scale structural changes were measured in a rabbit animal model from the following 
treatment groups: Sham, ovariectomized (OVX), OVX + alendronate (ALN), OVX + cathepsin K 
inhibitor (CatKI), and OVX + estrogen replacement therapy (ERT). AFM images were collected 
for 84 animals across all five treatment groups. A fibril-by-fibril analysis was conducted by hand-
coding fibrils into Parallel (collagen bundles or collagen sheets) or Oblique microstructures. In 
cortical bone, OVX increased the proportion of fibrils coded as Oblique and decreased the 
proportion of fibrils coded as Parallel with statistical significance (p < 0.05). Treatment with ALN 
or ERT partially prevented this change from occurring and treatment with CatKI completely 
prevented this change from occurring within error. 
An automated imaged level analysis was conducted using an autocorrelation technique and 
calculating a fibril alignment parameter (FAP) to describe the degree of local collagen fibril 
alignment in an image. At this level of hierarchical structure, OVX altered trabecular bone and 
showed no changes to cortical bone. Treatment with CatKI prevented the trabecular 
microstructural change from occurring but also introduced a change to the cortical bone. Treatment 
with ALN altered both the cortical and trabecular microstructure. 
 Sites of collagen interactions with the collagen chaperone PEDF, pigment epithelium 
derived factor, were imaged in bone tissue by phase imaging during tapping mode AFM. Gold 
nanoparticles were used as a secondary tag on PEDF to allow detection of PEDF binding in tissue. 
PEDF bound heterogeneously and was detected between collagen fibrils with a low amount of 
alignment. 
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Chapter 1 
Introduction 
 
1.1 Negative Impact of Osteoporosis 
Osteoporosis, or “porous bone,” is a debilitating disease that causes low bone mass and 
increased bone fracture risk.1 According to the National Osteoporosis Foundation, 54 million 
Americans were affected by osteoporosis and low bone mass in December 2015.2,3 Osteoporosis 
is responsible for two million broken bones and $19 billion in medical expenses every year in the 
United States. One in two women and one in four men aged 50 or older will break a bone due to 
osteoporosis.2 Typically located in the spine, hip, or wrist,1 the number of osteoporotic fractures 
surpasses breast cancer, stroke, and heart attacks.4 
This disease has a powerful negative impact on the quality of life.1,5 Bones weakened from 
osteoporosis can fracture with stresses as minimal as sneezing or bumping into furniture.2 As the 
bone weakens, chronic localized pain may develop. Spinal vertebrae are often affected by 
osteoporosis and a vertebrae fracture or collapse can lead to a stooped or hunched posture, along 
with acute, debilitating pain.5 Many people who suffer from osteoporosis will ultimately develop 
depression due to the isolation, and loss of lifestyle caused by compromised mobility, along with 
pain and generally declining quality of life.2,5 
When a senior breaks a bone, they often need long term nursing care.5 20% of seniors who 
break a hip will die within one year due to complications with the broken bone itself or the surgery 
to treat the broken bone.2 Within this demographic, the stress caused by the trauma of the broken 
bone and displacement from the customary domicile during the extended rehabilitation period, 
triggers an accelerated death rate from pneumonia, heart attack and stroke. 
Osteoporosis is sometimes called a “silent disease” because there are often no symptoms 
until there is a broken bone. A woman’s risk of breaking a hip is equal to her combined risk of 
breast, uterine, and ovarian cancer. Post-menopausal women are particularly susceptible to 
osteoporosis because of the dramatic decrease in estrogen after menopause.6–8 The disease has 
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become more common as the age of life expectancy has increased.1,2,6,9 A 50 year old woman in 
the United States has a 40% lifetime risk of an osteoporotic fracture. A third of women and an 
eighth of men over age 80 will have a hip fracture at some point and 15-20% of those people will 
die from complications.6 With such a large portion of the population suffering from the disease, it 
is important that accurate and reliable diagnostic methods are in place as well as treatments for 
individuals who battle this disease. 
 
1.2 Current Diagnostic Methods 
The standard procedure for the diagnosis of osteoporosis is to measure bone mineral 
density (BMD) using dual-energy X-ray absorptiometery (DEXA). An individual’s BMD value is 
compared to the distribution of BMD values for young adults to generate a T-score. A T-score 
indicates how much a given BMD value deviates from the mean BMD value in a population. For 
example, a T-score of -1.0 would mean that the BMD for that individual is one standard deviation 
lower than the mean BMD value for a population of young adults.4,10  
According to the World Health Organization (WHO), a T-score of ≤ 2.5 is diagnostic of 
osteoporosis.3,4 However, BMD is not always a good predictor of bone fracture risk and a large 
proportion of postmenopausal women who experience bone fractures have a normal T-score.11  As 
shown in Figure 1.1, a high bone turnover rate is associated with osteoporotic fractures 
independently of BMD.12 It is interesting to note that there is a higher incidence of osteoporotic 
fracture with a high BMD and high bone turnover rate than there is with low BMD, which is the 
diagnostic standard for osteoporosis. A high rate of bone remodeling can change the architecture 
of the bone without change the bone mass or BMD.4 This can have negative effects on the bone 
strength.4 
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Figure 1.1 Reprinted from Basic and Applied Bone Biology 2014; Burr and Allen4 
 
BMD and bone remodeling rate influence bone fracture risk independently as well as 
resulting in an even greater risk when both factors are present. Bone remodeling rates can be 
altered by estrogen depletion and various drug treatments, as described in the next several sections. 
The overall theme of this thesis is to understand how estrogen depletion and drug treatments alter 
the architecture of bone at the level of type I collagen fibrils, the primary protein component of the 
bone. 
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1.3 Effects of Estrogen Depletion on Bone Architecture and Bone Remodeling 
Estrogen plays a key role in bone mass homeostasis by inducing osteoclast apoptosis13 to 
suppress remodeling on both trabecular and endocortical surfaces. Production of receptor activator 
of the NF-КB ligand (RANKL) by osteoblasts and bone marrow stromal cells is inhibited by 
estrogen. In addition, estrogen increases the production of osteoprotegerin (OPG). When estrogen 
levels decline with menopause, the balance of RANKL and OPG is altered and the results are 
increased osteoclast differentiation, stimulation of osteoclast activation on bone surfaces, and 
reduction of osteoclast apoptosis. In summary, the loss of estrogen leads to an increase in 
osteoclast-mediated bone resorption.4,8 
The cellular changes caused by estrogen depletion lead to dramatic changes in the overall 
architecture of both cortical and trabecular bone. In addition to reduced bone volume, trabecular 
bone experiences a decrease in connectivity and thinning of the trabeculae. Cortical bone 
undergoes thinning over time and this is observed in the long bones as well as the femoral neck 
and cortical shell of lumbar vertebrae. In the long bones, cortical thinning is often compensated 
for by apposition of bone at the periosteal surface, which increases the diameter. This 
compensation is not observed elsewhere. In addition to cortical thinning, the femoral neck also 
experiences increased porosity.4,13  
 
1.4 Osteoporosis Treatments 
1.4.1 Bisphosphonates 
Bisphosphonates are a class of antiresorptive agents that are structurally similar to 
pyrophosphate and contain a “P-C-P” backbone (Figure 1.2).6,14 Pyrophosphate binds to 
hydroxyapatite in bone and is involved in various biochemical pathways once taken in by 
osteoclasts. The substitution of a carbon atom for the central oxygen atom makes the molecule 
more stable and prevents hydrolysis inside the cell.14 There are two side chains available for 
substitution on the central atom of the bisphosphonate. A hydroxyl group on one side chain 
increases the affinity for hydroxyapatite and the other side chain determines potency of the drug.14 
Alendronate (Figure 1.2) was the first orally available bisphosphonate in the United States 
for the treatment of postmenopausal osteoporosis1 and is marketed by Merck. Bisphosphonates 
enter the osteoclast during resorption and the downstream cellular effects of the drug lead to a loss 
of the osteoclast’s characteristic “ruffled border” morphology and resorptive activity. These 
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changes lead to apoptosis of the osteoclast. The nitrogen containing bisphosphonates, such as 
alendronate, are hypothesized to induce osteoclast apoptosis by interfering with the prenylation of 
membrane proteins and thus the signaling function of key regulatory proteins.6,14  
Several concerns with the long-term use of bisphosphonate drugs have led to the 
development of alternative therapies for osteoporosis.15,16 Bone formation and resorption are 
coupled processes. The antiresorptive activity of bisphosphonates ultimately leads to suppression 
of bone formation due to the elimination of signaling between osteoclasts and osteoblasts. In 
addition, the sustained secondary mineralization of older bone coupled with a decrease in bone 
turnover results in an overall increase in tissue mineral content. This is initially an advantage 
because the bone becomes stiffer. However, over time the bone will become more mineralized and 
more homogeneous. Long-term use of bisphosphonates can lead to brittle bones and this is a 
concern that has led to the development of alternative drugs.6 
 
1.4.2 Cathepsin K Inhibitors 
Cathepsin K is a lysosomal protease highly expressed by osteoclasts and is the primary 
collagenase responsible for osteoclast-mediated bone resorption. Studies have shown that 
treatment with a cathepsin K inhibitor (CatKI) in rats17 and monkeys18 produces biochemical 
markers of bone resorption and increased BMD. Numerous CatKIs have been developed for the 
treatment of various conditions including osteoporosis, osteoarthritis, metastatic bone disease, and 
atherosclerosis.19 In order to treat post-menopausal osteoporosis, it is important to minimize off-
target activity of the drug and maximize selectivity for the cathepsin K enzyme in bone. A 2007 
review by Black and Percival goes into great detail on the many structural designs considered for 
a therapeutic cathepsin K inhibitor.19 The most successful drug candidate to date is MK-0822, or 
odanacatib, developed by Merck. Odanacatib (Figure 1.2) is the most selective and bioavailable 
CatKI developed to date. This drug has been successful in clinical trials and is near the end of the 
FDA approval process for the treatment of post-menopausal osteoporosis.20 
Merck, Inc. has worked develop alternatives to odanacatib. In 2010, MK-0674 (Figure 1.2) 
was reported as a CatKI that is structurally similar to odanacatib, is orally bioavailable, and is a 
good drug candidate with a different metabolic profile from odanacatib.21 
 6 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Chemical structures 
for bisphosphonates and various 
cathepsin K inhibitors 
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1.5 Rabbit Animal Model to Study the Effect of Drug Treatments on Nano and Micro 
Structure of Type I Collagen in Bone 
The effects of alendronate and the CatKI L-235 (Figure 1.2) have been studied in a rabbit 
animal model developed at Merck Research laboratories.22 New Zealand white female rabbits were 
weight-randomized into two groups: Sham + vehicle or ovariectomy (OVX) + vehicle. The OVX 
animals were again weight-randomized and either received no drug or received alendronate, the 
CatKI L-235, or estrogen replacement therapy. The animal models are summarized in Figure 1.3.  
  
Figure 1.3 Summary of animals used to study effects of drug treatments on nano and micro 
structure of type I collagen in bone. a) “Data Set I” in Chapter 2, page 13; Chapter 3, page 22. 
b) “Data Set II” in Chapter 2, page 13. 
a) 
b) 
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Atomic force microscopy (AFM) was used to study the nano and micro structure changes 
of type I collagen23 in response to the treatments outlined in Figure 1.3. Several metrics of 
assessing nano/micro structure were used. An analysis of D-spacing can be found in chapters 2 
(page 13), 3 (page 22), and 5 (page ##). For many years, the D-spacing of type I collagen fibrils 
was thought to be a single value of 67 nm. The origin of D-spacing in collagen fibrils was first 
presented by the Hodge Petruska model24 and is shown in Figure 1.4. In this model, 300 nm 
tropocollagen molecules stack in an organized fashion to produce a pattern of “gap” and “overlap” 
regions. These gap and overlap regions generate a single 67 nm spacing. The Orgel model for the 
origin of D-spacing (Figure 1.5) also only accounts for a single value.25–27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The Hodge Petruska model 
Type I collagen peptides self-assemble into triple helical tropocollagen molecules that are 
300 nm in length. The Hodge Petruska model proposes that these tropocollagen units stack 
to produce areas of “gap” and “overlap” that are observed as the D-spacing. 
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 AFM is capable of measuring the D-spacing for individual collagen fibrils.28 This method 
removes averaging and generates a distribution of D-spacing values. Type I collagen exhibits a 
distribution of values in both mineralized and non-mineralized tissue including bone, skin, tendon, 
and teeth.29 In addition, the distribution of D-spacing values can change as a function of disease.30 
These studies provided the motivation to analyze the D-spacing distributions as a function of 
estrogen depletion and drug treatment in the rabbit animal model (Chapters 2 and 3). 
This thesis reports the development of two additional metrics to access changes in nano 
and microstructure of type I collagen in bone. The proportion of collagen fibrils in a Parallel or 
Oblique microstructure is reported in chapter 231 for cortical bone (page ##) and chapter 3 for 
trabecular bone (page ##). In this method, fibrils with a defined D-spacing were hand coded as 
being in a Parallel microstructure or Oblique microstructure. The Parallel microstructure 
consisted of collagen fibrils that were aligned in the same direction in bundles (3-15 fibrils 
associated with one another) or sheets (>20 fibrils continuous with surrounding bone). Oblique 
microstructures contained fibrils with a wide array of angles between. The proportion of fibrils in 
these two categories was measured for estrogen depleted and drug treated groups. 
 
 
Figure 1.5 The Orgel model 
Reprinted from Orgel et al. 2006 Proc. 
Natl. Acad. Sci. USA 103 (24) 9001-900526 
 
In this model, collagen molecules pack 
quasihexagonally to produce microfibrils. 
Each collagen molecule interacts with two 
other collagen molecules and forms an 
intermicrofibrillar crosslink at a C-
terminal peptide.  
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A larger scale assessment of structure was analyzed by calculating a fibril alignment 
parameter (chapter 3, page 22). This method considers fibril structure at the level of an entire AFM 
image. The Parallel/Oblique method had limitations because it is time intensive and requires 
measurements to be put into one of only two categories. The development of the fibril alignment 
parameter was an automated approach that removed the hand coding and allowed images to be 
given a measurement with a continuous variable. 
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Chapter 2  
Alteration of Type I Collagen Microstructure Induced by Estrogen Depletion 
can be Prevented with Drug Treatment 
Meagan A Cauble, Edward Rothman, Kathleen Welch, Ming Fang, Le T Duong, Brenda L 
Pennypacker, Bradford G Orr, and Mark M Banaszak Holl 
Reprinted from BoneKEy Reports 4, 697 (2015) 
© 2015 International Bone & Mineral Society  
 
2.1 Introduction 
Reduction of estrogen level affects over 75 million people worldwide by inducing 
Osteoporosis and Osteopenia, decreasing overall bone quality, and increasing susceptibility to 
fracture.1,2 Clinical and scientific assessments have focused heavily on bone mineral density 
(BMD) as the primary assay of bone quality and drug treatment outcomes. However, BMD has 
demonstrated limitations for predicting bone fracture and understanding the roles of estrogen in 
bone quality, formation, and resorption.3–5 In particular, BMD is unable to assess changes in Type 
I collagen structure that are key to understanding bone toughness. The structural changes that occur 
in Type I collagen matrix under conditions of estrogen depletion and drug treatment remain largely 
unknown. Here we show that the Type I collagen microstructure is altered by estrogen depletion 
and that this change is largely prevented by treatment with a Cathepsin-K inhibitor (CatKI) and 
partially prevented with bisphosphonate or estradiol treatment. These observations are particularly 
surprising for the bisphosphonate drug, which was developed to help maintain BMD, and 
represents a new understanding of biochemical activity for this decades-old therapeutic. The ability 
of an inhibitor of the collagenase cathepsin-K to prevent estrogen-induced changes in Type I 
collagen microstructure is also previously unknown. 
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2.2 Results 
Changes in Type I collagen microstructure and nanomorphology are conveniently 
measured using atomic force microscopy (AFM).6,7 Recent AFM studies indicated changes in the  
nanomorphology of the Type I collagen fibrils in ovariectomized (OVX) sheep8–10 and rats.11 In 
order to explore the effect of estrogen depletion and compare efficacy of CatKI and alendronate 
(ALN) drug treatments, the rabbit OVX model was developed by Merck Inc., as human CatKI’s 
exhibit similar potency for the rabbit enzyme and the adult rabbit skeleton undergoes substantial 
cortical Haversian remodeling (unlike the rodent).12 Nine-month-old New Zealand white female 
rabbits (Data Set I) underwent the following treatments: sham operation + vehicle (n = 11), 
ovariectomy + vehicle (OVX; n = 12), OVX + 200 g/kg ALN, 3 × a week for 27 weeks (n = 12) 
and OVX + 10 mg/kg CatKI L-235 daily for 27 weeks (n=13). Treatments were initiated three 
days after surgery. Data Set II consisted of 6-month-old New Zealand white female rabbits that 
underwent the following treatments: sham operation + vehicle (n = 12), ovariectomy + vehicle 
(OVX; n = 12) and OVX + 0.05 mg/kg 17β-estradiol (ERT) 3 × a week for 13 weeks (n = 12). 
Treatments were initiated 17 days after surgery. Both studies were performed in prevention mode 
with drug dosing initiated soon after surgery. Sample sets were stored in 95% ethanol. Rabbit 
cortical femur samples were polished for 90 s, followed by sonication for 5 min. Demineralization 
was carried out for 90 min (9-month-old) or 120 min (6-month-old) using 0.5 M EDTA at pH 8.0. 
The samples were sonicated for 5 min before imaging. We confirmed that ethanol fixation did not 
change the overall distribution of collagen fibril D-spacings or microstructure by direct 
comparison with the analysis of fresh, frozen rabbit bone. AFM images were obtained using 
tapping mode in air using silicon cantilevers (tip radius 10 nm, force constant 40 N/m and 
resonance frequency 300 kHz). Details on sample preparation, imaging and image analysis 
protocols for Type I collagen in bone have been previously published.6 Images were obtained from 
locations from across the full 1.00 × 0.75-cm section of the femur mid-diaphysis (Figure A.1). All 
images were acquired in the plane parallel to the long bone axis and obtained from polished regions 
100-300 m below the bone surface. No variation in collagen structure was noted as a function of 
the polishing depth employed. Image acquisition for the mid-diaphysis sections proceeded using 
the follow procedure. First, 30 × 30-m scans were obtained in six regions of the 1.00 × 0.75-cm 
bone imaging area. These were followed by 10 × 10 m scans, and finally the 3.5 × 3.5-m scans 
employed for image analysis. This approach ensured that the nano- to micro-scale analysis of 
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collagen fibrils was distributed across the 1.0 × 0.75-cm imaging area. An average of six 30 × 30-
m scans and thirteen 3.5 × 3.5-m scans were obtained per animal. From these regions, the 
average of 75 fibrils per animal was obtained. The local microstructure about each fibril was 
examined and coded as either Parallel or Oblique. In a given image area, it is thus possible for 
both Parallel and Oblique fibrils to be present. Furthermore, the assignment is indicative of a local 
order between fibrils with a length scale of a few hundred nanometers. The assessment does not 
provide evidence, one way or the other, of overall micron- to millimeter-scale order as typically 
measured using X-ray diffraction methods.     
Exemplar images highlighting 
the features observed in the local 
structural organization of the fibrils are 
illustrated in Figure 2.1. We noted two 
major qualitative features in the 
images: (1) Parallel regions of fibrils 
with subclasses of bundles (3-15 fibrils 
aligned in parallel with defined edges) 
and sheets (> 20 fibrils aligned in 
planar, parallel manner); (2) Oblique 
regions of fibrils exhibiting an angular 
range of fibril orientation. For all 
samples, the nanomorphology of individual fibrils, as quantified using the metric of the D-spacing, 
was measured, and each fibril was coded (blinded of the sample origin) for its local microstructure. 
Fibrils coded as present in bundles or sheets (Figure 2.1a) were grouped together as Parallel 
regions. A number of other features were also coded including fibril pairs and individual fibrils 
crossing bundles or sheets (Figure A.2). Roughly half of the fibrils observed were present in 
structures without the same degree of parallel alignment, exhibited a wide range of fiber-fiber 
angular dispersion and were classified as being present in Oblique regions (Figure 2.1b). A total 
of 5673 individual fibrils were classified from 1081 3.5 × 3.5-m images from a total of 94 animals 
across the seven experimental groups. The coding and frequency of Parallel and Oblique 
observations are summarized in Table 2.1. In all cases, the Parallel and Oblique codings captured 
Figure 2.1 AFM images illustrating Parallel and 
Oblique regions of Type I collagen fibrils. a) Parallel 
region showing multiple aligned fibrils (yellow 
arrows); b) oblique region showing multiple fibrils 
with varying alignment (yellow arrows). 3.5 × 3.5 µm 
image. 
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95% of all measured fibrils. Additional exemplar images for the Sham, OVX, ALN, CatKI and 
ERT treatments are provided in Figure A.4. 
To assess the significance of the differences in proportion of fibrils that are in Parallel and 
Oblique regions by the treatment group, we employed a logistic regression model using 
generalized estimating equations (GEEs),13 with correlations between any two pairs of 
observations within the same animal being constant, estimated from the data. The proportion of 
each type of fibril was compared for each treatment versus sham using a binary outcome, Yij, 
where Yij = 1 if the fibril was in a given microenvironment (that is, Parallel or Oblique) and Yij = 
0 if the fibril was not, with a logit link function. All s.e.’s were computed using the robust Huber-
White estimates. The GEE model that was employed is shown below: 
log𝑖𝑡(𝑝ij) = log (
𝑝ij
1 − 𝑝ij
) = 𝛽0 +  ∑ 𝛽𝑡
𝑇−1
𝑡=1
Treatment𝑡 
 
where pij = probability (Yij = 1) for fibril I in animal j, 0 is the intercept, and t fits the effect of 
treatment t, t = 1 to T, with treatment T being the reference category. 
Post hoc comparisons of collagen fibril orientations were then carried out between 
treatment groups, using a Bonferroni correction for multiple comparisons with statistical 
significance assigned for P-values below 0.05.   
Compared to Sham, the OVX-treated animals in Data Set I had a 17% decrease (P-value = 
0.0045) in the proportion of fibrils occurring in Parallel structures and an 18% increase (P-value 
= 0.0026) in the proportion of fibrils occurring in Oblique structures. ALN treatment was 
previously observed to function as an antiresorptive leading to a BMD higher than that in the 
vehicle-treated group.12 In this study, ALN treatment resulted in a frequency of collagen fibril 
observations intermediate between Sham and OVX values, although the differences in proportions 
of fibrils in Parallel and Oblique regions in these treatments were not significant. The bone 
resorption inhibitor CatKI also gave intermediate values for the frequency of collagen fibril 
observations and showed even less shift from the initial Sham values, with none of the comparisons 
versus other treatments being significant. Statistically, the changes in proportion of fibrils in 
Parallel and Oblique regions for the drug-treated sample were not significantly different from the 
Sham samples. These data indicate that the drugs prevent the OVX-induced change in collagen 
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microstructure in addition to their traditionally understood roles of preventing decreases in BMD. 
For the OVX treatment in Data Set II, an 18% decrease (P-value 0.0188) was observed in the 
proportion of fibril occurrence in Parallel structures and a 20% increase (P-value 0.0048) was 
observed in the proportion of fibril occurrence in Oblique structures compared with Sham. ERT 
treatment resulted in a partial prevention of change in the collagen microstructure, although the 
difference in ERT versus Sham in proportion of Parallel region fibrils was not significant 
(P=0.0961), whereas the difference in the proportion of Oblique fibrils was significant (0.0185). 
The magnitude of observed changes was similar to ALN treatment and less effective compared 
with CatKI treatment in preventing microstructure change. Analysis of the D-spacing variation for 
all seven treatments showed a range of values between ~58 and 70 nm, consistent with previous 
observations of D-spacing distribution.6,8,14 However, no shift of the D-spacing values was 
observed for these samples, unlike the previous comparison for Sham and OVX sheep samples 
(Figure A.3).8,9  
 
Table 2.1 Frequency of Type I collagen fibrils observed in Parallel and Oblique microstructures 
 
2.3 Discussion 
OVX is a common model used to study the effects of estrogen depletion.8,9,15–17 
Pennypacker et al.12 applied the OVX model to study osteopenia in rabbits using the samples 
described herein and demonstrated osteoclastic bone resorption resulting from estrogen depletion. 
On the basis of the strong positive correlations between the experimental strength parameters and 
the tissue bone mineral content from animals from the same study, it was demonstrated that there 
were no obvious treatment-related changes in the material properties of vertebrae and femurs in 
Treatment 
No. of 
fibrils 
No. of 
animals 
Frequency in 
Parallel 
Microstructures 
(%, s.e.) 
Frequency in 
Oblique 
Microstructures 
(%, s.e.) 
  
Microstructure 
Frequency 
Difference 
Data Set I Sham 825 11 52 (5) 45 (5) 7 (10) 
 OVX 808 12 35 (5) 63 (5) -28 (10) 
 ALN 971 12 40 (5) 57 (5) -17 (10) 
 CatKI 1001 13 47 (5) 49 (5) -2 (10) 
       
Data Set II Sham 579 12 53 (5) 42 (5) 11 (10) 
 OVX 728 12 35 (5) 62 (5) -27 (10) 
 ERT 761 12 41 (4) 58 (4) -17 (10) 
 18 
 
the OVX rabbits treated with odanacatib or ALN for 27 weeks. Here, we directly examined the 
effects of estrogen deficiency and two different bone resorption inhibitors at the microfibril 
structure level and observed changes in the relative frequency of fibril occurrence in local Parallel 
and Oblique microstructures. The link between increased resorption and the changes reported here 
to Type I collagen fibril microstructure remains unknown; however, related studies in the literature 
provide clues to possible mechanisms. In the mouse model, OVX reduces proteoglycan levels.11 
Furthermore, biglycan and decorin knockout mice have abnormal collagen fibril morphologies.12 
We hypothesize that reduced proteoglycan levels perturb the interactions between adjacent fibrils, 
resulting in a change to the microstructure. Cathepsin-K, a collagenase secreted by osteoclasts, 
cleaves proteoglycans from the fibril exterior before degrading the primary fibril structure.18 OVX 
results in increased osteoclast activity coupled to increased cathepsin-K activity. This is directly 
countered by ERT therapy resulting in partial prevention of the collagen fibril microstructure 
changes. Strikingly, application of CatKI, which can prevent proteoglycan cleavage directly at the 
level of enzyme activity, gives almost complete prevention of fibril microstructure change. By 
way of contrast, treatment with a bisphosphonate is known to induce a change to osteoclast cell 
morphology and eventual cell death.19 Thus, ALN reduces the amount of bone resorption, but also 
indirectly lowers the activity of cathepsin-K enzyme, which is consistent with observation that 
ALN treatment partially prevents changes to Type I collagen microstructure. Recently, Reznikov 
et al.20 reported that the human lamellar bone consists of two different materials that differ 
substantially in terms of collagen fibril order. The connection between our fibril-level local 
organization classification (Parallel versus Oblique) and their observation of ‘ordered’ and 
‘disordered’ materials is not clear at this time; however, changes in the relative quantities of the 
‘ordered’ and the ‘disordered’ materials as a function of estrogen depletion and drug treatment are 
also a possible explanation of our data. These changes could also be related to the impacts of 
proteoglycan levels as discussed above. 
In summary, a quantitative analysis of Type I collagen fibril organization indicates a 
significant decrease in fibrils appearing in Parallel structures such as bundles and sheets (18%) 
and a concomitant increase in fibrils appearing in Oblique structures, on OVX treatment of 6- and 
9-month old rabbits. ALN and ERT drug treatments partially prevent the microstructure changes 
(12% decrease in Parallel structures), and CatKI treatment almost completely prevents the 
structural change (5% decrease in Parallel structures). The change in Type I collagen 
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microstructure induced by OVX is a previously unrecognized aspect of the impact of estrogen 
depletion on bone quality. In addition, the amelioration of these microstructure changes is a 
previously unrecognized mechanism of drug activity. 
 
2.4 Materials and Methods 
All rabbit femur samples were obtained from Merck Research Laboratory, West Point, PA, 
USA, and treatment of these animals was previously described in detail.12 Sample preparation and 
the AFM imaging methods employed in this work have also been described in detail.6 All imaging 
was carried out in air using a PicoPlus 5500 AFM (Agilent, Santa Clara, CA, USA) employing 
tapping mode with VistaProbes T300R probes (NanoScience, Phoenix, AZ, USA; nominal radius 
10nm, force constant 40 N/m, resonance frequency 300 kHz). Line scan rates were set at 2 Hz or 
lower at 512 lines per frame. Image analysis and measurements were performed using the SPIP 
software (Image Metrology, Horsholm, Denmark). 
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Chapter 3. 
Estrogen depletion and drug treatment alters the microstructure of type I 
collagen in bone 
In collaboration with Matt Muckley, Dr. Ming Fang, Prof. Jeffrey A. Fessler, Dr. Kathleen 
Welch, Prof. Edward D. Rothman, Prof. Bradford G. Orr, Dr. Le T. Duong, and Prof. Mark M. 
Banaszak Holl  
 
3.1 Introduction 
Reduction of estrogen levels is known to negatively impact bone quality and increase the 
likelihood of fracture for over 75 million people worldwide including 54 million people and 1.5 
million fractures per year in the United States.1–4 The widespread prevalence of Osteoporosis 
induced by the estrogen reduction in postmenopausal women has spurred a search for quantitative 
measures that can serve to probe the changes in bone structure and predict fracture. Bone mineral 
density (BMD) measurements have proven useful as a primary assay but are only indirectly 
sensitive to changes in collagen matrix structure and have limited predictive ability for bone 
fracture.5 For these reasons, analytical tools that can assess changes in the collagen matrix as a 
function of estrogen reduction and drug treatment are highly desired.6,7   
In our previous work, we characterized the effect of ovariectomy-induced estrogen 
depletion (OVX) and long-term treatment with alendronate (ALN), a cathepsin-K inhibitor L-
006235 (CatKI), and 17β-estradiol (ERT) administered in prevention-mode on collagen fibril 
organization in rabbit cortical bone by classification of fibrils as existing in Parallel regions 
(bundles and sheets) or Oblique regions.8 When analyzed by this method, OVX treatment resulted 
in a decrease in the percentage of collagen fibrils in the Parallel orientation. This microstructural 
change was partially prevented by treatment with ALN and fully prevented by treatment with 
CatKI. We now extend the Parallel/Oblique analysis to rabbit trabecular bone and introduce a 
new, fully automated method to characterize an image-level fibril alignment parameter (FAP) for 
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type I collagen fibrils in cortical femur and trabecular lumbar vertebrae. The addition of trabecular 
bone is important to this study because it is remodeled faster than cortical bone and changes in 
bone mass due to estrogen reduction are more pronounced. For this reason, many studies focus on 
the trabecular bone as a key metric for developing biological and structural understanding of 
osteoporosis.9  
In this study, we first focus on a comparison of the collagen fibril structure between the 
cortical and trabecular bone and then extend the comparison to include OVX, OVX + ALN, and 
OVX + CatKI treatments. Surgical ovariectomy (OVX) is a common model used to induce 
estrogen depletion.10–14 ALN is an orally available bisphosphonate developed by Merck and 
marketed as Fosamax. Although the bisphosphonates are effective in the clinic, similar to other 
potent antiresorptives, long term therapy have been associated with the increased incidences of 
several rare conditions including osteonecrosis of the jawbone and atypical fractures of the 
femur.1,15–17 Bisphosphonates work by binding to bone mineral and then inducing apoptosis after 
being taken in by osteoclasts.18 This mechanism of action is problematic because eliminating 
osteoclasts alters cell signaling between osteoclasts and osteoblasts that is critical to maintaining 
bone mass homeostasis. Recently, Merck Research Laboratories has developed a novel cathepsin 
K inhibitor (odanacatib) that inhibits cathepsin K, a collagenase secreted by osteoclasts, without 
killing the cell.9 This drug is effective because cathepsin K is the primary collagenase in bone and 
plays an important role in osteoclast mediated bone resorption.19 The animal model used in this 
study consists of 9 month old female New Zealand white rabbits chosen because of their 
similarities to humans with respect to the cathepsin K enzyme and Haversian remodeling in 
cortical bone.8,9 The treatment groups included Sham-operated + vehicle (n = 11), OVX + vehicle 
(n = 12), OVX + alendronate (ALN, 600 µg/kg/wk, s.c.) (n = 12) and OVX + L-235 (CatKI, 10 
mg/kg, daily, p.o.) (n = 13) in prevention mode for 27 weeks. Note, L-006235 (L-235) is 
structurally related and displays similar potency and selectivity as odanacatib in preclinical models 
of osteoporosis.9 
We have imaged both cortical femur and trabecular lumbar vertebrae rabbit bone using 
atomic force microscopy (AFM). The image sets were analyzed using two approaches. First, 
individual fibrils with a measurable D-spacing in the images were coded as being present in local 
Parallel or Oblique arrangements using the method described previously.8 For the first time, we 
have extended the imaging and the Parallel/Oblique analysis to trabecular bone with OVX and 
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drug treatments. This analysis approach relies on hand coding of the images, is very time 
consuming, omits fibrils without a measurable D-spacing, and is limited to the approximation of 
assigning fibrils with just two classifications. An automated image analysis that could function at 
the level of the entire image and provide a continuous variable characterizing the extent of fibril 
organization was highly desired. To achieve this goal, we developed a second analysis approach 
that employs autocorrelation of image patches to compute a vector field that approximates fibril 
alignment. We then used that vector field to generate a fibril alignment parameter (FAP) based on 
an information-theoretic entropy calculation for each image as well as to form maps indicating the 
spatial alignment within a given image. We applied this approach to both the cortical and trabecular 
sample sets. 
Comparing the cortical to trabecular collagen structure, the frequency of fibrils in the 
Parallel microstructure decreased and the frequency of Oblique microstructures increased. The 
cortical and trabecular bone resulted in the same average FAP value; however, the distribution of 
FAP values derived from the individual regions contained more high FAP values (low alignment) 
for the trabecular case and low FAP value (high alignment) for the cortical case. Both observations 
are consistent with our qualitative assessment of the relative amount of fibril alignment observed 
for the two bone types. Treatment with ALN resulted in a shift towards lower FAP values for 
cortical bone and a partial prevention of the increase in the frequency of Oblique fibrils; however, 
for trabecular bone higher FAP values were obtained coupled to an increase in the frequency of 
Parallel coded microstructure. Treatment with CatKI resulted in a shift towards higher FAP values 
for cortical bone, with no change in the Parallel/Oblique frequencies, and no change in FAP values 
for trabecular bone although the frequency of Parallel coded microstructure increased similar to 
the ALN treatment. In summary, both image analysis approaches indicate: 1) cortical collagen and 
trabecular collagen alignment differs significantly; 2) OVX and drug treatment can impact the 
alignment of the collagen fibrils in both cortical and trabecular bone; 3) the impact of OVX, OVX 
+ ALN, and OVX + CatKI treatment on collagen fibril alignment differs between the cortical and 
trabecular bone.   
    
3.2 Methods 
3.2.1 Bone Preparation and AFM Imaging 
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All samples were obtained from Merck Research laboratories and stored in 95% ethanol.8,9 
Rabbit cortical femur images analyzed were from our previously published data set.8 There were 
a total of 663 images (3.5 µm2) for cortical femur samples taken from 48 animals (11 Sham, 12 
OVX, 12 OVX + ALN, and 13 OVX + CatKI). Trabecular bone from the lumbar vertebrae of the 
same animals was added to the current study. All images were obtained blind to treatment type. 
AFM imaging of the lumbar trabecular samples was quite challenging due to the heterogeneous 
organization of trabecular spicules and the fragility of the trabeculi. Methods development required 
an extended period and resulted in the loss of 1 Sham, 1 OVX, 0 ALN, and 1 CatKI samples from 
the data set. The final animal counts for the lumbar vertebrae are as follows: Sham + vehicle (n = 
10), OVX (n = 11), OVX + ALN (n = 12), and OVX + CatKI (n = 12). The lumbar vertebrae 
samples were prepared by sectioning a region of the caudal end and mounting onto a steel AFM 
puck. Bone marrow was mechanically removed using forceps followed by polishing the sample 
on a wheel for 2-4 minutes using a 3-micron diamond suspension and sonication in nanopure water 
for five minutes to remove the polishing solution. The surface collagen was demineralized by 
shaking in 0.5 M EDTA pH = 8.0 for 30 minutes at room temperature. Sonication was repeated 
for five minutes prior to air drying before imaging in tapping mode. All imaging was performed 
in air at room temperature with a conical AFM probe (nanoScience Instruments; Aspire conical 
tapping mode AFM probes; 300 kHz, 40 N/m, radius 8 nm). Initial scans for trabecular lumbar 
vertebrae images where acquired using a 10 µm x 10 µm image area on a trabecular rod structure. 
A set of 3.5 µm x 3.5 µm images were acquired for each region with a total of 526 images (3.5 µm 
x 3.5 µm) available for the calculation of the fibril alignment parameters from the 45 animals. 
2,187 and 3,605 fibrils were identified for D-spacing measurement and coding as being in a 
Parallel microstructure (bundle or sheet) or Oblique microstructure for the trabecular lumbar 
vertebrae and cortical femur, respectively. 
 
3.2.2 Analysis of D-spacing 
The D-periodic axial/gap overlap spacing (D-spacing) was measured for the blinded 
lumbar trabecular bone samples. A total of 511 fibrils were measured for Sham, 662 for OVX, 533 
for OVX + ALN, and 654 for OVX + CatKI. Full details on the instrument calibration, controls 
for instrument thermal drift, and the use of 2D-Fourier transforms to accurately measure the fibril 
D-spacing have been previously published.14,20,21 We note that thermal instrument drift, instrument 
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calibration and tilt angles in the D-spacing must be properly accounted for to obtain accurate 
distributions.20,22   
 
3.2.3 Parallel and Oblique Fibril Classification 
Each fibril was coded as either Parallel or Oblique to assess the local microstructure 
surrounding individual collagen fibrils. This hand-coding was performed while blinded to 
treatment group. The Parallel/Oblique classification has been presented in detail previously.8 
Briefly, fibrils were given the parallel classification if they existed in a bundle of 3-15 fibrils 
aligned in parallel with defined edges or in a sheet of > 20 parallel, aligned fibrils that are 
continuous with adjacent bone. An Oblique classification was given when fibrils were in a 
microstructure with a wide range of fibril-fibril angular dispersion. Topography and amplitude 
images were both used for making this classification. The results of this analysis for the cortical 
femur have been previously reported.8 This fibril-by-fibril analysis was implemented for the 
trabecular lumbar vertebrae in the same way it was for the cortical femur.  
 
3.2.4 Fibril Alignment Parameter (FAP) Calculation and Analysis 
To quantitatively assess the degree of fibril alignment in the AFM images, we developed 
and employed an autocorrelation approach and an information-theoretic entropy metric to 
determine a fibril alignment parameter (FAP). The FAP provides reproducible and quantitative 
image-to-image and sample-to-sample comparisons of the collagen fibril alignment. This 
autocorrelation approach was developed after the sample blinding had been removed. Amplitude 
images were employed for this analysis since this image mode highlights D-spacing and fibril-to-
fibril features as opposed to overall topographic slope. A high pass FFT-based filter with a square-
shaped frequency response of width 8000 nm−1 (i.e., excluding frequencies below 0.004 nm−1) was 
applied to the images to prevent artifacts in the autocorrelation resulting from local variation in 
the amplitude gray scale within an image. A patch size of 64 x 64 pixels (439 x 439 nm) was 
selected, corresponding to a region containing six to seven D-spacings along a fibril length and 
about six to seven fibrils in width. An array of patches across the 3500 x 3500 nm image was 
created by shifts of 4 pixels in the x and y directions. Each patch in the array was then correlated 
with neighboring patches. The analysis performed a restricted search to obtain the maximum 
autocorrelation from patches in a shift range between 7 and 14 pixel shifts (corresponding to 48 
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nm to 96 nm; this is within the ~60-70 nm range of the repeated structures present from D-spacing 
and individual fibril widths). Each patch orientation was represented by a vector that indicates the 
angle and magnitude of the highest neighboring patch correlation. The result of this process is 
illustrated by the quiver plot overlaid on the AFM image in Supplemental Figure B.3 and B.4.  
We used the information theoretic entropy as a summary statistic of the patch alignment 
vectors. The information theoretic entropy is defined for a probability density function as follows 
(eq 1): 
𝜀 =  − ∑ 𝑝(𝑥𝑗)ln (𝑝(𝑥𝑗))𝑗=1                                                                             (1) 
where xj represents a possible local alignment angle and p(xj) is the “probability” of that angle 
occurring. This parameter quantifies the degree of fibril alignment in the distribution. An empirical 
probability distribution was created based on the angles and lengths of the alignment vectors. The 
entropy of this empirical distribution yields a parameter that captures the extent of collagen fibril 
alignments due to the properties of the entropy function. For these entropy calculations, instead of 
using the exact empirical probability, we weighted the probability of an angle by the confidence 
in that alignment angle (eq. 2), 
𝑝(𝑥𝑗) ≈  
К𝑗
∑ К𝑗𝑗
                                                                                                           (2) 
where Кj corresponds to the arrow scaling for the direction at location j. This is the FAP that is on 
a scale of 0 to 1 with 0 resulting from vectors that are completely aligned or parallel (angle of 0) 
and 1 resulting from vectors with no dominant alignment. The approach has the advantage of also 
being able to quantify a full range of oblique angles from parallel to perpendicular. Heat maps 
were produced from the vector fields with areas of high fibril alignment shown in red and areas of 
low alignment shown in blue (Figure B.5, B.6, B.7, and B.8). 
 
3.3 Results and Discussion  
Trabecular bone in the vertebrae is a complex tissue composed of a bi-continuous network 
of mineralized collagen trabeculae interspersed with marrow.25 Previous AFM studies on 
trabecular bone have noted the complexity of the woven collagen fibrils do not seem to match a 
simple twisted plywood model of fibril orientation and alignment.26 AFM images of human 
osteoporotic trabecular bone from a fractured femoral head have been reported; however, the 
medication history of the individual is not known.27 In order to gain a greater understanding of the 
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differences between the collagen structure in cortical and 
trabecular bone, and between normal tissue and tissue affected 
by OVX, OXV + ALN, and OVX + CatKI treatments, we have 
examined a group of 48 rabbits including sham-operated 
(Sham), ovariectomized (OVX), OVX + ALN, and OVX + 
CatKI treatments. Imaging the trabecular bone in the rabbit 
lumbar vertebrae was substantially more challenging than the 
imaging of the cortical femur bone. For the cortical femur 
region, the bone itself is robust and after polishing and 
demineralizing a large, continuous field of collagen is 
available for study. As illustrated in Figure 3.1, the center 
region of a lumbar vertebrae contains trabecular spicules 
separated by large gaps that had been filled with marrow. 
Imaging regions were selected on the trabeculae, which even after polishing remained rough on 
the micron scale as compared to similarly prepared cortical femur bone. Exemplar pictures of both 
the cortical femur and lumbar vertebrae are provided in Figure B.1. The following discussion of 
the changes in collagen fibril structure is organized in terms of increasing hierarchical structural 
scale. We first focus on changes in the D-spacing values within fibrils. The discussion then turns 
to a hand coded analysis of the local fibril organization for each of the fibrils assessed for its D-
spacing value. Finally, we present a newly developed analysis were we quantify the fibril 
alignments in a 3.5 × 3.5 µm image field. Thus, our structural analysis starts on a ~50-100 nm 
scale, progresses to a ~70-700 nm scale, and ends assessing alignment over a 3,500 nm region. 
 
3.3.1 Analysis of D-spacing Variation 
The measurements of 2,187 trabecular lumbar vertebrae and 3,605 cortical femur fibril D-
periodic axial/gap overlap spacing (D-spacing) values distributed across the Sham, OVX, OVX + 
ALN, and OVX + CatKI treatments are summarized in Figure B.2. Neither the average D-spacing 
values nor the distribution of the values revealed significant differences between Sham, OVX, 
OVX + ALN, and OVX + CatKI treatments for either the cortical femur sample7 or the lumbar 
vertebrae data sets when considered as a whole. 
0.1 cm 
Figure 3.1 Optical image of 
rabbit lumbar vertebrae section. 
Images were obtained at the 
polished top face of the 
trabeculai. 
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In five-year-old Columbia-Ramboulliet cross sheep, ovariectomy-induced estrogen 
depletion induces changes in type I collagen D-spacing distributions.14 Wallace et al. concluded 
that OVX (3 animals; 182 fibrils) resulted in a decrease in the mean D-spacing and a shift in the 
overall D-spacing distribution towards lower values in ovine bone (p < 0.001) when compared to 
the Sham treatment group (3 animals; 168 fibrils).14 As discussed, there are no changes observed 
in the overall D-spacing distributions for either the rabbit cortical or trabecular samples. The 
rabbits used in the current animal model are skeletally mature (rabbits reach skeletal maturity by 
eight months).28 In addition, the rabbits were sacrificed 27 weeks after ovariectomy which is 
sufficient time to observe changes induced by estrogen depletion9 In the ovine study, the animals 
used by Wallace et al.14 were also skeletally mature and allowed to reach peak bone remodeling 
rates post-OVX. Markers for bone remodeling in sheep peak after 3-4 months.29 It is not clear if 
the varying effects estrogen depletion are species dependent or if the changes observed by Wallace 
et al. in ovine bone would be minimized with a larger sample size. In cynomolgus monkeys, a 
sample size of 15-20 animals is required to provide statistical power when comparing Sham and 
OVX treatment groups.13  
 
3.3.2 Analysis of Animal-to-Animal Variability in Bundle D-Spacing 
 We examined the distribution in D-spacing that exists for fibrils coded as existing in 
bundles only and in this way excluded the very disperse 50% or so of measurements arising from 
the more heterogeneous Oblique fibrils as well as fibrils coded as existing in a sheet microstructure 
(Figure 3.2). The D-spacing distribution for bundle collagen fibrils for the trabecular vertebrae of 
Sham animals is illustrated in Figure 3.2a. The average D-spacing value for the Sham animals is 
65.9 nm (0.5, standard error) whereas the average value for the OXV, OVX + ALN, and OVX + 
CatKI animals is 65.4 nm (0.5), 64.9 nm (0.5), and 64.8 nm (0.5), respectively. While there were 
no significant differences among the means across treatments (p = 0.4573) there were significant 
differences in the degree of animal-to-animal variability across treatments (p = 0.02 by likelihood 
ratio test). Fitting a variance components model within each treatment, including a random effect 
for animal, there is zero variability estimated between animals in the Sham treatment. The OVX 
treatment exhibited a non-significant animal to animal variability in the D-spacing of trabecular 
fibrils coded as being in a bundle microstructure (p = 0.074; likelihood ratio chi-square test). 
Significant between animal variability was observed in both the OVX + ALN and OVX + CatKI 
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treatment groups (p < 0.0001 in each treatment). This analysis of bundle D-spacing was also 
performed for the cortical femurs, as shown in Figure 3.3. A likelihood ratio test for the equality 
of the variances showed that there were no significant differences in animal to animal variability 
across the four treatments for the cortical femurs (p = 0.64). 
Treatment with ALN or CatKI introduced animal-to-animal variability in the bundle D-
spacing values for trabecular bone and not cortical bone. The faster remodeling rate of trabecular 
bone is one possible source of this observed difference between the two types of bone. 
 
Figure 3.2 Boxplots of the D-spacing distribution of the collagen fibrils located in trabecular 
bundles obtained for Sham, OVX, OVX + ALN, and OVX + CatKI treatment groups. Both of the 
drug treatments introduced significant animal-to-animal variability in the bundle D-spacing (p < 
0.0001 by likelihood ratio Chi square test). There were two ALN animals that did not contain any 
fibrils that were coded as being in a bundle. One of those two animals had both sheet and Oblique 
microstructures and the other animal only had Oblique microstructures. 
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Figure 3.3 Boxplots of the D-spacing distribution of collagen fibrils located in cortical femur 
bundles obtained for Sham, OVX, OVX + ALN, and OVX + CatKI treatment groups. There were 
no significant differences in the animal-to-animal variability across the four treatment groups (p = 
0.64, likelihood ratio test). 
 
3.3.3 Parallel and Oblique Fibril Classification 
All fibrils quantified in terms of D-spacing values were hand-coded as existing in either 
Parallel or Oblique microstructures. The percentage of Oblique or Parallel fibrils was examined 
using a Generalized Estimating Equation (GEE) approach30 that takes into account the correlation 
among observations in the same animal (Table 3.1). As previously described,8 the percentage of 
Oblique fibrils in rabbit cortical femur was estimated to be 18% greater in the OVX group than in 
the Sham group (p = 0.0026). However, the percentage of Oblique fibrils in rabbit trabecular 
lumbar vertebrae was 4% lower in the OVX group than in the Sham group and this difference was 
non-significant (p = 0.6415). The full statistical analysis is described in chapter 2.8 All differences 
in the percentage of fibrils in a given microstructure for trabecular bone were non-significant (p > 
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0.05). The OVX + CatKI has 13% more fibrils coded as parallel than the Sham group and this was 
the largest difference observed in the trabecular bone (p = 0.1084).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1 Frequency of Type I Collagen Fibrils Observed in Parallel and Oblique Microstructures 
 
We also compared the percentage of fibrils coded as Parallel in trabecular versus cortical 
bone within each treatment group using the GEE model described above. The cortical OVX group 
had a percentage of Parallel fibrils that was 12% lower than the trabecular OVX group and this 
difference was marginally significant (p = 0.0596). All other comparisons for the percentage of 
Parallel fibrils were non-significant (p > 0.05). The same comparisons for the percentage of 
Oblique fibrils were also non-significant (p > 0.05). All comparisons with their p-values can be 
found in Tables 3.2 and 3.3. 
 
 
 
 
 
 
Treatment 
# of 
fibrils 
# of 
animals 
Frequency in 
Parallel 
Microstructures 
(%, std error) 
Frequency in 
Oblique 
Microstructures 
(%, std error) 
Cortical Sham 825 11 52 (5) 45 (5) 
Femur OVX 808 12 35 (5) 63 (5) 
 ALN 971 12 40 (5) 57 (5) 
 CatKI 1001 13 47 (5) 49 (5) 
      
Trabecular Sham 511 10 44 (7) 56 (7) 
Lumbar OVX 662 11 47 (5) 52 (5) 
Vertebrae ALN 532 12 46 (6) 53 (6) 
 CatKI 654 12 57 (5) 43 (5) 
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Comparison 
p-value 
Cortical Sham and Trabecular Sham 0.2971 
Cortical OVX and Trabecular OVX 0.0596 
Cortical OVX + ALN and Trabecular OVX + ALN 0.4684 
Cortical OVX + CatKI and Trabecular OVX + CatKI 0.1315 
Table 3.2 Comparisons of the percentage of fibrils coded as Parallel in cortical versus trabecular 
bone in each treatment group 
 
Comparison p-value 
Cortical Sham and Trabecular Sham 0.1958 
Cortical OVX and Trabecular OVX 0.9684 
Cortical OVX + ALN and Trabecular OVX + ALN 0.7866 
Cortical OVX + CatKI and Trabecular OVX + CatKI 0.8118 
Table 3.3 Comparisons of the percentage of fibrils coded as oblique in cortical versus trabecular 
bone in each treatment group 
 
3.3.4 Fibril alignment parameter analysis of AFM images from cortical femur and trabecular 
lumbar bone 
Our previous observations that OVX and drug treatment impact collagen structure in bone,8 
and that the dispersion of D-spacing values was affected by the collagen packing microstructure,23 
drove our interest in developing quantitative approaches to the analysis of the fibril packing on a 
multi-micron scale. The new approach presented here has the advantages of being fully automated, 
avoiding the tedious nature of the blinded hand coding, and generates average alignment parameter 
values that vary continuously from 0 (fibrils aligned in parallel) to 1 (fibrils exhibit no dominant 
alignment) for each image. This quantitative output allows ready comparison of images both 
within and between sample sets. 
Fibril alignment parameter (FAP) calculations were performed for a total of 663 images 
(3.5 µm2) for cortical femur samples and 526 images (3.5 µm2) for trabecular lumbar vertebrae 
samples across 48 animals. The average FAP values for sham femur and sham lumbar vertebrae 
were the same (0.9 ± 0.1); however, the distributions of the FAPs differed with the cortical femur 
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having more images in the 0.4 to 0.8 parameter range (more alignment) and fewer images in the 
0.9 to 1.0 range (less alignment) (Figure 3.4). The histograms are not Gaussian distributions and 
were plotted as cumulative density functions to perform statistical comparisons. Exemplar images 
are provided in Figure 3.4b along with the CDF to illustrate how changes in image-level fibril 
alignment correspond to the changes in FAP. A Kolmogorov-Smirnov (K-S) test indicated the 
cortical and trabecular distributions for Sham tissue were significantly different (p = 0.000).  
 
 
Figure 3.4 Distribution of FAP values in cortical and trabecular bone. a) The sham cortical femurs 
and trabecular lumbar vertebrae exhibit a non-Gaussian distribution of FAP values with an average 
value of 0.8 ± 0.1. b) Cumulative density functions of FAP values for Sham cortical femurs and 
trabecular lumbar vertebrae. The sham lumbar vertebrae were shifted towards higher FAP values 
(less collagen alignment) with statistical significance (p = 0.000). 
 
3.3.5 Effect of OVX on FAP distributions in cortical femur and trabecular lumbar bone 
OVX and Sham animals showed no difference in their average FAP (0.8 ± 0.1) or 
distribution of values (p = 0.481 for cortical femur; p = 0.067 for trabecular vertebrae) (Figures 
3.5a and 3.5b). Although Sham cortical and Sham trabecular bone exhibit significantly different 
FAP distributions (p = 0.000), under OVX treatment the lumbar vertebrae FAP distribution moves 
toward that of the OVX cortical femur distribution and the two CDFs are no longer statistically 
different (p = 0.153) (Figure 3.6a). In other words, for the case of cortical femur bone, the OVX 
CDF distribution does not differ from Sham (p = 0.481); however, the lumbar trabecular FAP 
distribution for OVX treatment is no longer significantly different from that for OVX cortical bone 
(p = 0.153). Recall that the comparison between OVX and Sham animals did show a statistically 
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significant difference in microstructure when considering the classification into Parallel and 
Oblique structures (Table 3.1).8 The FAP values for the lumbar trabecular bone were 0.9 ± 0.1 for 
Sham and 0.8 ± 0.1 for OVX. The distribution of OVX values shifted slightly to higher alignment; 
however, the shift is not significant as assessed by the K-S statistic (p = 0.067) (Figure 3.5b). 
 
3.3.6 Effects of ALN and CatKI Drug Treatments on FAP distributions in cortical femur and 
trabecular lumbar bone 
Drug treatments did not change the average FAP values of 0.8 ± 0.1 and 0.9 ± 0.1, 
respectively, for the cortical femur and trabecular lumbar bone, but they did affect the distributions 
(Figure 3.5). For the cortical femur data set, OVX + ALN treatment resulted in a significant 
increase in the number of regions of parallel alignment (decrease in FAP) as compared to OVX (p 
= 0.012). Treatment with OVX + CatKI resulted in a significant decrease in the number of regions 
of parallel alignment (increase in FAP) as compared to Sham (p = 0.007) and OVX + ALN (p = 
0.000) but not to OVX (p = 0.078). For the lumbar vertebrae data, the OVX + ALN treatment 
resulted in a significant decrease in the numbers of regions of parallel alignment (increase in FAP) 
as compared to OVX (p = 0.000). It is notable that the shift direction is opposite direction than that 
observed for cortical bone. Treatment with OVX + CatKI also resulted in a significant decrease in 
the numbers of regions of parallel alignment (increase in FAP) as compared to OVX (p = 0.010).  
The change in FAP distribution as a function of bone type and drug treatment is 
summarized in Figure 3.5c. For any given treatment, the change in FAP distribution relative to 
Sham is different for cortical and trabecular bone. One possible origin for this difference is the 
faster remodeling rate of trabecular bone relative to cortical bone. This difference in remodeling 
rate could alter the relative amounts of aligned/unaligned collagen and this would produce a 
difference FAP value distribution. When considering only one type of bone at a time (cortical or 
trabecular), the drug treatment (ALN or CatKI) induces a different change in the FAP distribution 
relative to Sham. ALN and CatKI have different mechanisms of action that could potentially 
explain these differences. ALN binds to bone mineral and is taken into the osteoclast during bone 
resorption and induces apoptosis of the osteoclast.18 In contrast, CatKI inhibits cathepsin K, the 
primary collagenase responsible for osteoclast-mediated bone resorption, and bone resorption is 
prevented without a decrease in bone formation.9 
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Figure 3.5 Distribution of FAP values for Sham, OVX, and drug treated bone in cortical femur (a) 
and trabecular lumbar vertebrae (b). All eight groups had the same average FAP value (0.8 ± 0.1 
for cortical Sham, cortical OVX, cortical OVX + ALN, and trabecular OVX and 0.9 ± 0.1 for 
cortical OVX + CatKI, trabecular Sham, trabecular OVX + ALN, and trabecular OVX + CatKI). 
(a) For cortical bone, the distribution of FAP values did not change after ovariectomy (p = 0.481). 
In comparison to Sham, drug treatment after ovariectomy resulted in a shift towards more order (p 
= 0.201) with ALN treatment and more disorder (0.007) with CatKI treatment. (b) In comparison 
to Sham, the distribution of FAP values for OVX is shifted towards more order (p = 0.067), 
treatment with alendronate shifts towards more disorder (p = 0.054), and treatment with CatKI has 
little effect (p = 0.889). (c) A summary of these changes in comparison to Sham. 
 
3.3.7 Summary of FAP distribution observations 
Sham animals have significantly different FAP distributions for cortical and trabecular 
bone with cortical femur having lower FAP values (more aligned) and trabecular lumbar vertebrae 
having higher FAP values (less aligned). OVX treatment shifts the trabecular distribution towards 
lower FAP values and the cortical and trabecular distributions are no longer significantly different 
from one another. Treatment with ALN following ovariectomy impacts both cortical and 
trabecular bone with cortical bone shifting towards lower FAP values and trabecular bone shifting 
towards higher FAP values. Treatment with CatKI only impacts cortical bone and shifts the 
distribution towards the trabecular distribution with higher FAP values. 
 37 
 
 
Figure 3.6 Cumulative density function of FAP values for estrogen depleted and drug treated 
animals in data sets I and III. Ovariectomy resulted in no change to the FAP distribution for cortical 
bone (0.481) and a shift towards lower FAP (more order) in the trabecular bone (p = 0.067). 
Treatment with alendronate resulted in the trabecular bone becoming less aligned (p = 0.054) and 
the cortical bone becoming more ordered (p = 0.201). In contrast, treatment with CatKI did not 
alter the extent of order/disorder for trabecular bone (p = 0.889) but did shift the cortical bone 
towards more disorder (p = 0.007). When comparing the distributions between femur and lumbar 
vertebrae within a treatment group, OVX is the only group that does not have a significant 
difference (Sham, p = 0.000; OVX, p = 0.153; OVX + ALN, p = 0.000; OVX + CatKI, p = 0.016). 
 
3.3.8 Relationship between FAP distributions and BMD 
 The bone mineral density (BMD) data for trabecular lumbar vertebrae samples in this 
animal study is published in Pennypacker et al. and a summary of the results are shown in Figure 
 38 
 
3.7.9 The Sham and OVX + drug treatment samples all have the same BMD within error. The 
estrogen depleted animals had a statistically significant lower BMD, as expected.  
 
Figure 3.7 Bone mineral density (BMD) for LV 3-5 (blue) and LV 3-4 (green). OVX rabbits had 
a significantly lower BMD compared with Sham (p < 0.01 for LV 3-5, p < 0.05 for LV3-4). 
Treatment with OVX + ALN and OVX + CatKI fully prevented BMD loss (p < 0.01). Data adapted 
from Pennypacker et al. 2011. 
 
The lumbar vertebrae samples imaged for the AFM analysis used lumbar vertebrae 4. Recall that 
the distributions of FAP values in trabecular bone showed a marginally significant shift towards 
lower values (p=0.067), or more alignment, under the OVX treatment condition (Figure 3.6a). 
Under the OVX + CatKI treatment condition, both BMD and FAP values (p=0.889) do not differ 
from Sham. Interestingly, under the OVX + ALN treatment condition (Figure 3.6b), the BMD did 
not differ from Sham but the FAP values exhibited an increase (less alignment) that was marginally 
significant (p = 0.054). Additional work is needed to understand how these changes in BMD and 
FAP relate to bone quality and mechanical properties. 
 
3.3.9 Relationship of D-spacing, parallel/oblique coding, and FAP to biological mechanism 
and structure. 
An important biological action of estrogen in bone is to induce apoptosis of osteoclasts.31,32  
Estrogen depletion leads to the prolonged life of those cells and increased bone resorption. 
Increased bone formation simultaneously develops and an overall high-turnover state develops 
which leads to changes in bone quality and/or bone loss. Estrogen depletion led to changes in the 
distribution of FAP values for trabecular lumbar vertebrae but not cortical femur. Although the 
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mechanism for this change is unknown, it could be related to the differences in estrogen receptors 
(ER). Trabecular bone primarily has the ERβ isoform and cortical bone primarily has the ERα 
isoform. If estrogen signaling for apoptosis is selective for one isoform over the other, then this 
could potentially explain the FAP changes observed. In addition, treatment with ALN after OVX 
resulted in changes to the FAP values for both cortical and trabecular bone. ALN does not use the 
estrogen receptor to kill the osteoclast so it makes sense that ALN is altering both cortical and 
trabecular bone. 
 
3.4 Conclusions 
 As expected, trabecular lumbar vertebrae had less aligned collagen than cortical femur in 
the Sham animals. The fibril alignment parameter applied to the AFM data in this study showed 
that ovariectomy induced estrogen depletion results in trabecular lumbar vertebrae and cortical 
femur having the same degree of alignment. Furthermore, drug treatments impact cortical femur 
and trabecular lumbar vertebrae differently. OVX followed by treatment with alendronate resulted 
in a change in the order for both cortical femur and trabecular lumbar vertebrae. The cortical femur 
became more aligned and the trabecular lumbar vertebrae became more less aligned. In contrast, 
treatment with the cathepsin K inhibitor prevented changes in the distribution of alignment in 
trabecular lumbar vertebrae from occurring. The cortical femur, however, was shifted towards less 
alignment. 
 Ovariectomy induced estrogen depletion alters microstructure at different hierarchical 
levels for cortical and trabecular bone in rabbits. In rabbit cortical femur, OVX altered 
microstructure at the individual fibril level. In trabecular lumbar vertebrae, OVX altered 
microstructure at a scale that is relevant at the micron level, as evidenced by the change in FAP 
value distribution. In order to effectively treat post-menopausal osteoporosis, it will be important 
for drug treatments to target the appropriate level of hierarchical structure being affected by the 
disease. 
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Chapter 4. 
Binding of pigment epithelium derived factor (PEDF) in rabbit femur is 
dependent on type I collagen microstructure 
In collaboration with: Phillip Yang, Rachel Merzel, Prof. Bradford G. Orr, and Prof. Mark M. 
Banaszak Holl 
 
4.1 Introduction 
 Pigment epithelial derived factor (PEDF) is a non-inhibitory member of the serpin class of 
proteins with various biological functions including anti-angiogenesis, anti-vasopermeability, anti-
tumor, and neurotrophic activities.1 This 50 kDa protein is expressed ubiquitously in humans.2,3 In 
bone, PEDF is primarily expressed and secreted by osteoblasts 
and is highly expressed at areas of active bone formation.4 
Direct binding of PEDF to type I collagen has been 
characterized and the binding consists of ionic interactions 
between a negatively charged area on the surface of PEDF and 
positively charged residues in collagen.5 As seen in Figure 4.1, 
the aspartic acid and glutamic acid residues highlighted in red 
make up a negatively charged region on PEDF that is thought 
to interact with positively charged residues in type I collagen. 
This proposed binding site is comprised of the following 
residues on PEDF: E41, E42, E43, D44, D64, D256, D258, E290, E291, 
E296, E300, and E304.5 On type I collagen, PEDF binds with high 
affinity to KGXRGFXGL sequences in the triple helix. There 
are two binding sites on the human α1(I) chain that bind PEDF 
with high affinity: KGHRGFSGL at residues 87-95 and 
IKGHRGFSGL at residues 929-938.6 There is a large amount 
of overlap between the binding motifs for PEDF and 
Figure 4.1 3D structure of 
human PEDF (PDB ID 1IMV) 
with proposed collagen binding 
site highlighted in red. 
Reprinted from Meyer et al.5 
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heparin/heparin sulfate proteoglycans (HSPG) on type I collagen.5,6 The heparin/HSPG binding 
motif is KGHRG(F/Y). The sequence-specific interaction between PEDF and collagen suggests 
that binding is a highly regulated process.6 
 We have used atomic force microscopy to characterize binding patterns of PEDF in cortical 
rabbit femur. The microstructure of collagen fibrils in this tissue is heterogeneous. On average, 
52% of fibrils that have a defined D-spacing are aligned Parallel to adjacent fibrils and are part of 
a larger structure (collagen bundle or sheet). 45% of fibrils are Oblique to surrounding fibrils. The 
remaining 3% are in rare microstructures such as fibril pairs or fibrils perpendicular to a bundle. 
This method for analysis of microstructure in bone (Parallel/Oblique fibrils) has been fully 
described.7 We have successfully imaged the binding locations of PEDF with respect to collagen 
microstructure. Our findings demonstrate that PEDF does not bind homogeneously in cortical 
rabbit femur. PEDF binding is concentrated at areas between microstructures with highly aligned 
collagen fibrils or between collagen fibrils. Binding is rarely observed on or within the collagen 
fibrils themselves.  
 
4.2 Methods 
4.2.1 Sample Preparation and Initial AFM Imaging 
 Nine month old New Zealand white rabbit bones were obtained from Merck Research 
laboratories and stored in 95% ethanol.7,8 Sections of the cortical femur were polished with a 
polishing wheel using a 3 µm diamond suspension in preparation for imaging with atomic force 
microscopy (AFM). Demineralization was achieved by suspending the samples in 0.5 M EDTA 
pH = 8.0 for 90 minutes while shaking at room temperature. The sample was sonicated for 5 
minutes in nanopure water both before and after demineralization. After the sample was allowed 
to air dry, AFM imaging was performed in air at room temperature in tapping mode (Nanoscience 
Instruments; Aspire conical tapping mode AFM probes; 300 kHz, 40 N/m, radius 8 nm). Initial 
scans were 30 µm × 30 µm in area. Subsequent images were areas within the initial scan area and 
were 10 µm × 10 µm and 3.5 µm × 3.5 µm. The 3.5 µm2 images are the size scale that qualitative 
comparisons will be made after binding with PEDF. In some instances, a series of 50 µm × 50 µm 
scans were obtained with varying offset values to assist in locating the same 3.5 µm2 imaging area 
after PEDF binding. 
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4.2.2 Preparation of Solutions 
 Stock solutions of 25-50 nM PEDF were prepared in the following buffer: 20 mM Tris pH 
7.5 and 150 mM NaCl. The stock solutions were aliquoted and then frozen at -80ºC until ready for 
use in an experiment. The day of an experiment, a solution of 0.1 M DTT was prepared. 
Immediately before the experiment, DTT was added to the PEDF aliquots so that the final solution 
used for the experiment was either 25 or 50 nM PEDF, 20 mM Tris pH 7.5, 150 mM NaCl, and 2 
mM DTT.  
 The stock solution of streptavidin-Au nanoparticles were stored at 4ºC. The day of an 
experiment, an aliquot of the stock solution was diluted with buffer (5 mM sodium azide, 0.1% 
BSA, and 5 mM Tris pH 7.5) so that there would be an equimolar ratio of streptavidin and PEDF 
(i.e. 50 nM PEDF and 50 nM streptavidin-Au).  
 
4.2.3 AFM imaging of Rabbit Femur Exposed to PEDF (Schemes 4.1 and 4.2) 
4.2.3.1 Binding PEDF and Attaching Secondary Tag in Separate Steps (Scheme 4.1) 
Following the initial imaging procedure (described in 4.2.1), the sample was removed from 
the AFM and 30 µL of solution containing PEDF was deposited as a droplet onto the polished 
bone surface. The solution remained as a droplet on the polished surface for 10 minutes at room 
temperature. After the incubation period, the liquid was wicked away from the surface with a 
Kimwipe. Then, 30 µL of the streptavidin-Au solution was deposited as a droplet and remained 
for ten minutes prior to wicking. The surface was gently rinsed with additional buffer (5 mM 
sodium azide, 0.1% BSA, and 5 mM Tris pH 7.5). The rinsing procedure involved depositing the 
buffer and wicking it away multiple times. 
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Scheme 4.1 Method 1 of exposing the rabbit femur to PEDF for binding experiments.  
 Step 1: Concentration of PEDF-strep tag solution was either 25 nM or 50 nM; 30 µL of 
solution was deposited onto the surface 
 Step 2: Rinsing buffer: 20 mM Tris pH 7.5, 150 mM NaCl, and 2 mM DTT; Incubation 
time was 10 minutes  
 Step 3: 30 µL of solution was deposited onto the surface. The concentration of streptavidin-
gold nanoparticles (Step 3): 25 nM or 50 nM; The concentration for this solution is 
referring to the concentration of streptavidin protein. The gold nanoparticles are 10 nm and 
are attached to the streptavidin protein. The concentration of streptavidin was always the 
same as the concentration of PEDF used in Step 1. 
 Step 4: Rinsing buffer: 5 mM sodium azide, 0.1% BSA, and 5 mM Tris pH 7.5.  
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4.2.3.2 Pre-Mixing PEDF/streptavidin-Au before PEDF Binding to Bone (Scheme 2) 
15 µL of the PEDF solution (25 or 50 nM) and 15 µL of the streptavidin-Au nanoparticle 
solution (25 or 50 nM) were combined and mixed for 5-10 minutes. All 30 µL of the mixed solution 
were deposited as a droplet and the allowed to incubate at room temperature for 10 minutes. The 
liquid was wicked away with a Kimwipe and the surface was gently rinsed with buffer (5 mM 
sodium azide, 0.1% BSA, and 5 mM Tris pH 7.5). 
 
 
Scheme 4.2 Method 2 of exposing the rabbit femur to PEDF for binding experiments.   
 Step 1: Concentration of PEDF-strep tag solution was 25 or 50 nM; Concentration of 
streptavidin-gold nanoparticles was 25 nM or 50 nM; 5-10 min incubation time  
 Step 3: Rinsing buffer 5 mM sodium azide, 0.1% BSA, and 5 mM Tris pH 7.5; 5-10 min 
incubation time 
 
4.2.3.3 Streptavidin-Gold Exposure as a Control Experiment (Scheme 4.3) 
Control experiments were performed without exposing the bone to PEDF. This allowed us 
to interpret our data without mistakenly identifying non-specific binding of gold nanoparticles as 
a PEDF binding event. It also allowed us to make sure that our rinsing procedure was removing 
all unbound gold nanoparticles. If the control experiment showed no gold nanoparticles, then the 
 48 
 
gold nanoparticles in experiments from Schemes 4.1 and 4.2 must be a result of PEDF binding. 
For these experiments, 30 µL of a streptavidin-gold nanoparticle solution that was either 25 or 50 
nM was deposited onto the surface of the bone. The concentration was calculated for the 
streptavidin protein. After incubating for 10 minutes at room temperature, the solution was wicked 
away with a Kimwipe and rinsed with buffer (5 mM sodium azide, 0.1% BSA, and 5 mM Tris pH 
7.5). 
 
 
Scheme 4.3 Control Experiment   
Step 1: 25 nM or 50 nM streptavidin-gold solution (concentration refers to the concentration of 
streptavidin) 
Step 2 Rinsing buffer: 5 mM sodium azide, 0.1% BSA, and 5 mM Tris pH 7.5; incubation time of 
10 minutes 
 
4.2.4 Infrared Spectra using combined AFM-IR 
 Additional imaging was done with nanoIR2 by Anasys Instruments (Santa Barbara, 
California). First, a tapping mode image was taken to identify the gold nanoparticles in the phase 
contrast image (Tapping Mode NIR2Probes for nanoIR2, 75 kHz, 107 N/m, Anasys Instruments). 
Images taken on the nanoIR2 were comparable to the images obtained using the Agilent 5500 
AFM. This similarity was necessary so that features being identified by IR in the nanoIR2 were 
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the same features that were detected using the Agilent 5500 AFM. Then, the tip was engaged in 
contact mode and an IR spectrum was obtained. The Au nanoparticles did not have a peak in the 
IR spectrum that the instrument can measure. However, when the laser shines on gold, there will 
be a greater intensity in the absorbance than when the laser shines on the bone or bone mineral. 
This phenomenon, called signal enhancement, was used to identify the presence of gold 
nanoparticles. IR spectra were obtained at various locations in the 3.5 µm2 image using the same 
laser power. These locations were hand-selected based on the features observed in the phase image. 
IR spectra were obtained both at these sites of phase contrast as well as varying distances from 
those features. The absorbance intensity for the amide I and amide II peaks (approximately 1690 
and 1580 cm-1 for these samples) were compared for all locations measured. Gold nanoparticles 
were identified when phase contrast was coupled with an increase in IR absorbance at 1690 and 
1580 cm-1 relative to surrounding collagen without phase contrast. 
 
4.3 Results and Discussion 
 The PEDF protein is too small to be resolved in the context of the Type I collagen fibrils 
unless tagged with something that is both larger and has substantially different physical 
characteristics. We tagged our PEDF protein with 10 nm gold nanoparticles. Our motivation for 
tagging with gold was to utilize the phase image capability of tapping mode AFM. The phase 
image is a measurement of the phase shift of the oscillating cantilever. Variations in sample 
hardness, adhesion, and viscoelasticity alter sample-tip interactions and lead to a phase shift. By 
recording changes in the phase signal, materials with different properties can be distinguished from 
one another.  
Gold is much harder than collagen and was detectable in the phase image. In order to tag 
the PEDF protein, we used a recombinantly made protein with a streptavidin tag provided by Jan 
Gebauer and Ulrich Baumann (Universitat Zu Koln, Cologne, Germany). We purchased 10nm 
gold nanoparticles that were conjugated to streptavidin. The streptavidin tag binds to streptavidin 
on the gold nanoparticle and this binding event attaches the gold nanoparticle to the PEDF protein.  
Samples of rabbit femur exposed to PEDF through schemes 1 and 2 produced phase images 
with dark circular features. These same features were also detected in the topography and 
amplitude images. We believe the dark areas in the phase image after binding to PEDF in Figure 
4.2 indicate areas where PEDF-streptavidin gold is interacting with collagen. The gold 
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nanoparticles should be distinct from surrounding collagen in phase imaging because gold is much 
harder than collagen. The dark area in the phase image before exposure to PEDF is likely due to 
bone mineral. This issue is addressed in the discussion for Figure 4.3.  
The size of the features in the phase image after PEDF exposure provides additional 
evidence that these features are the gold nanoparticles. The size of the smaller dark features in the 
phase image are consistent with the size of the nanoparticles (10 nm, about 1/6 or 1/7 of the 
collagen fibril width). The PEDF appears to interact with the surface at the edges of collagen 
fibrils. 
 
 
Figure 4.2 AFM image before and after exposure to PEDF using Scheme 1. The dark area in the 
“before” image is likely due to mineral. The smaller dark areas in the “after” images are being 
interpreted as gold nanoparticles and PEDF binding events. 
 
 51 
 
As mentioned previously, bone mineral is also much harder than collagen and will look 
similar to gold in AFM phase images. One way to address this issue was to image at the same 
location before and after exposing the bone to PEDF solutions. Figure 4.3 is a representative set 
of images showing the results of this type of experiment. This experiments were carried out using 
the pre-mixing method described in Scheme 4.2. Before exposure to PEDF, no dark areas are seen 
in the phase image, meaning that no mineral is detected in the phase image. After exposure to the 
PEDF/streptavidin-Au solution, dark areas appear that were not present before. These areas are 
being interpreted as areas with gold nanoparticles and areas where PEDF is interacting with 
collagen. The gold nanoparticles bound primarily in between collagen bundles and collagen fibrils. 
The PEDF was not observed to bind on the collagen fibrils themselves.  
 
 
Figure 4.3 AFM image of the same location in rabbit femur before (top row) and after (bottom 
row) exposure to PEDF-Au nanoparticles. The dark areas in the phase image are PEDF-Au binding 
events. 
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 A control experiment was important to ensure that any gold identified on the bone surface 
is a result of PEDF/collagen interactions and not a result of non-specific binding of gold 
nanoparticles on the surface. The control experiment is described in Scheme 4.3 and the results 
are shown in Figure 4.4. Non-specific binding of gold nanoparticles to the bone surface was not 
observed. The features present in these images are likely mineral. The gold nanoparticles in 
Figures 4.2 and 4.3 were seen as dark circular features in the phase image. The features seen here 
are irregularly shaped and often brighter than surrounding bone. 
 
 
Figure 4.4 Exposure to streptavidin-Au nanoparticles in the absence of PEDF acts as a control 
experiment to observe non-specific binding events. 
 
IR spectroscopy was used for further evidence on the identification of the gold nanoparticles in 
the phase contrast image. For these experiments, the nanoIR2 by Anasys instruments was used. 
After we reproduced a phase contrast image that we believed to see gold nanoparticles, we obtained 
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IR spectra at the particles and at varying distances from the particles. Signal enhancement near the 
particles indicated that the particles were gold. Bone mineral does not cause signal enhancement. 
In addition to enhancement, we observed the introduction of a wave pattern when near a particle 
(Figure 4.5). 
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Figure 4.5 Signal enhancement suggests the presence of gold nanoparticles in the phase image. a) 
Signal enhancement is observed by an increase in absorbance for the location closer to the gold 
nanoparticles. b) Spectra obtained adjacent to a particle showed signal enhancement in addition to 
the presence of a wave pattern. 
 
a) 
b) 
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A loss of function mutation in the gene for PEDF, SERPINF1, results in the recessive bone 
disease osteogenesis imperfecta (OI) type VI.2,3 This type of OI is unique because collagen 
synthesis is not impaired and there are no amino acid mutations resulting in alterations in collagen 
structure.9 In OI type VI, there is an increase in osteoid tissue and an increase in the time it takes 
to mineralized newly formed bone. This phenotype is not observed for other types of OI.9 The 
bone matrix of patients with OI type VI has been characterized by Fratzl et al.9 and three 
nano/micro structural changes were reported with the diseased tissue: (1) mixture of highly 
mineralized bone matrix with areas of bone with low mineral content, (2) low mineralization 
around the boarder of lacunae with “heterogeneous and abnormally elongated fibrillary features,” 
and (3) more heterogeneity in mineral particle size, shape, and arrangement.9 In is interesting to 
note that a mutation in SERPINF1 changes the microstructure of bone matrix and binding of PEDF 
in healthy tissue is heterogeneous. 
 
4.4 Conclusions 
 Protein interactions between PEDF and collagen were detected in tissue using AFM with 
a gold nanoparticle as a secondary tag. The gold nanoparticles were also identified using IR 
spectroscopy. There was IR signal enhancement near the gold nanoparticles as well as the 
introduction of a wave pattern. The location of gold nanoparticles reflects the location of PEDF 
binding and the binding locations were identified with respect to collagen microstructure. PEDF 
binding was heterogeneous and observed to bind in between areas with highly aligned collagen 
fibrils and between collagen fibrils. Binding was not observed within the bundles or within the 
collagen fibril. 
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Chapter 5 
Type I Collagen Fibril Nanomorphology: D-spacing, Persistence Length, and 
the Microfibril to Fibril Transition 
In collaboration with Chelsea Finkbeiner, Phillip Yang, Dalia Antebi-Lerman, Prof. Bradford G. 
Orr and Prof. Mark M. Banaszak Holl 
Submitted to Langmuir 
 
5.1 Introduction 
Type I collagen molecules assemble to form the protein scaffold for bone, dentin, skin, and 
tendon.1-6 In addition to Type I collagen, these tissues contain other types of collagen, additional 
proteins, and, in the case of bone and dentin, hydroxyapatite mineral. The Type I collagen 
molecules, which are on the order of 1.5 nm in diameter and 300 nm in length, assemble with these 
additional components into complex hierarchical structures including microfibrils, fibrils, and 
fibers to form tissue structures that vary in size from microns to meters. The structural complexity 
and compositional heterogeneity of these materials has led to the use of simpler model systems for 
the exploration of Type I collagen structure and properties. The model systems allow study of 
structural properties in the absence of biological processing events including mineralization, cross-
linking, and protein chaperones.   
The assembly of collagen molecules into microfibrils and fibrils and elucidation of the 
details of the structure remains a challenging problem. Major techniques employed to shed light 
on these structures include electron microscopy (EM), X-ray diffraction (XRD), and atomic force 
microscopy (AFM). When comparing results between the different techniques, it is important to 
keep in mind the key advantages, limitations, and idiosyncrasies of each method. EM, the first 
method used to characterize collagen fibrils, evaluates modulation of electron density in space. 
EM provides structural data on the level of the individual fibril; however, it is important to keep 
in mind that the electron density patterns reported are typically not of the Type I collagen fibril 
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directly, but rather reflect the electron density of a negative or positive stain.7,8 EM data has also 
been acquired on polymer casts of Type I collagen fibrils.9 XRD is similar to EM in that it measures 
the spatial electron density of the sample; however, XRD is an ensemble method that averages 
over micron to millimeter spatial dimensions and does not provide data on the structure of 
individual Type I collagen microfibrils or fibrils. AFM is distinct from both EM and XRD in that 
it measures surface topography and is not a measure of internal fibril electron density. AFM is able 
to provide data on the level of the individual collagen molecule, microfibril, and fibril and does 
not require staining for image contrast.10  
Previous reports have described the use of reconstituted rat tail collagen self-assembled 
onto a mica substrate to form microfibril and fibril microribbons11,12 that retain key nano- to micro-
scale features of tissue-based collagen fibrils. AFM imaging provides a convenient, label-free 
method for the analysis of the resulting structures and provides quantitative, topographical 
information. We employed conventional silicon AFM probes with a nominal 10 nm tip diameter 
as well as carbon-nanotube (CNT) probes with a nominal 1 nm tip diameter in order to provide a 
new level of resolution of microfibril structure within the self-assembled fibril microribbons. 
Using these approaches, we have been able to estimate the number of collagen molecules present 
in the microfibrils and fibrils, the numbers of collagen molecules/microfibrils needed to generate 
a fibril with a multimicron persistence length, and the number of collagen molecules required to 
generate an AFM observable topographical D-spacing. The CNT probe also provided a high 
degree of resolution of the microfibrils making up large fibrils including the development of 
nanoscale banding perpendicular to the fibril axis. The nanoscale axial banding was evaluated 
using line scans to evaluate the distribution of dimensions observed and using Fourier transforms 
to assess the average dimensions of the repeating structure. 
These studies examining self-assembly of rat tail collagen on mica lead to several new 
quantitative conclusions regarding the relationship of Type I collagen microfibrils and fibrils. 
Consistent with the proposals of previous structural models,5,6,13-15 the smallest microfibrils were 
measured with cross-sectional areas consistent with the presence of five collagen molecules. These 
microfibrils, as well as larger structures consisting of ~5-8 of these microfibrils or about 40 
collagen molecules in cross-section, did not exhibit detectable axial spacings or a substantial 
persistence length. By way of contrast, fibrils containing greater than 10 microfibrils and about 90 
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collagen molecules in cross-section exhibited both axial spacing and micron scale persistence 
lengths.   
 
5.2 Experimental Section 
5.2.1 Type I Collagen Self-Assembly   
All samples were prepared from Type I collagen derived from rat-tail tendon (4.0 mg/mL, 
>90% purity by SDS-PAGE; BD Biosciences; Franklin Lakes, NJ). A collagen stock solution to 
be used for experiments was prepared by diluting the purchased 4.0 mg/mL collagen solution to 
1.65 mg/mL with 0.1% acetic acid. All solutions were stored at 4˚C. The mica substrate was glued 
onto steel atomic force microscopy pucks (SPI supplies; West Chester, PA). Mica was freshly 
cleaved by removing top layers with adhesive tape. A 25 g/mL solution of collagen in buffer (30 
mM Na2HPO4, 10 mM KH2PO4, 200 mM KCl) was prepared from the 1.65 mg/mL collagen stock 
solution and 30 L was deposited onto freshly cleaved mica. Samples were incubated at room 
temperature in a moist chamber for varying times from 20 to 120 minutes. The surface was rinsed 
with nanopure water followed by wicking the water from the surface with a paper towel to prevent 
drying artifacts. The sample was further dried under weak nitrogen flow for 5-10 minutes.  
 
5.2.2 AFM Imaging and Image Analysis.   
Samples were imaged in air using PicoPlus 5500 Atomic Force Microscopy (Agilent) in 
tapping mode. Two types of probes were employed: Silicon cantilevers (VistaProbes T300R, tip 
radius < 10 nm, force constant 40 N/m, resonance frequency 300 kHz; nanoScience Instruments; 
Phoenix, AZ) and Carbon Nanotube (CNT) containing cantilevers (FN-1 CNT tip, tip radius ~0.5 
nm, force constant 3 N/m, resonance frequency 60 kHz; K-Tek, Wilsonville, OR). The microscope 
was calibrated using a 100 nm pitch grid (2D-100; NANOSENSORS, Switzerland) using the 
methods previously described.16 Image analysis was carried out using SPIP and Gwyddion 
software using approaches described in previous publications.16,17 For Table 1, average values and 
standard deviations of full-width-at-half-maximum (FWHM), height, width, and cross-sectional 
area were generated from a minimum of 10 separate measurements. The number of collagen 
molecules for each microfibril or fibril bundle was estimated by dividing the measured cross-
sectional area by the cross-sectional area for a collagen molecule (1.46 nm2).   
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5.3 Results and Discussion 
Collagens are based on trimeric polypeptide chains, each of which includes a repeating 
Gly-X-Y triplet region where X and Y are often proline and hydroxyproline.1-3 The fibrillar-
forming class (types I, II, III, V, and XI) has an approximately 300 nm long, uninterrupted 
molecular triple helix with type I accounting for 70% of all collagens. The fibrils formed from 
packing and cross-linking of the molecular triple helix are found throughout the body in the 
extracellular matrices (ECMs) of teeth, bones, tendons, skin, arterial walls and cornea.18 The type 
I collagen fibrils exhibit a prominent axial spacing that has elicited substantial interest since the 
dawn of electron microscopy (EM). The axial spacing was first reported with measurements 
resolved at the level of the individual fibril in 1942 by Schmitt et al.19,20 A distribution of axial 
spacings centered at ~64 nm was observed for rat tail collagen. Cognizant that drying the tissue 
for EM studies could introduce artifacts into the measurements, Gross and Schmitt made plastic 
imprints of moist fibrils obtained from human skin in formvar and collodion and measured the 
structures of the plastic replicas.9 They obtained a slightly narrower distribution of axial spacings 
that ranged from 50 to 80 nm and was centered at 64 nm, but were able to rule out dehydration of 
the collagen fibril as the source of the dispersion in the axial spacings. Contemporaneous with 
these studies, the first X-ray diffraction measurements of type I collagen fibrils consistent with the 
EM results identified the presence of an axial spacing of ~64 nm.21,22 In 1963, the first model 
explaining how collagen molecules could pack to yield the observed fibrillar structure was 
developed by Hodge and Petruska.23 They proposed that molecules within a fibril are arranged in 
a staggered parallel alignment, resulting in “gap” and “overlap” regions to give a D-periodic axial 
gap/overlap spacing (D-spacing) that generates the axial electron density waves observed by the 
electron microscopy19,20 and X-ray studies.21,22 Single crystal X-ray diffraction studies have 
subsequently allowed the generation of a more sophisticated three-dimensional model of the 
average fibril structure consistent with five-stranded microfibrils that are supertwisted in the axial 
direction and quasi-hexagonally packed in the equatorial plane.13,24-26  
Although much of the field has focused on improving knowledge of the average structure 
of collagen fibrils and how it can be used to understand mechanical properties and disease,1,27 
numerous studies have appeared examining the structure at the level of the individual fibril. In 
these studies, distributions of D-spacings have been observed for healthy tissue,28 diseased and 
drug treated tissue10,16,29-41 and for self-assemblies of collagen fibrils on surfaces.17 Despite the 
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observation of the D-spacing distribution for a wide variety of tissues types (bone, teeth, tendon, 
skin) the structural origin of the distribution and the relationship of the distribution to the average 
fibril models built with a single D-spacing value (Hodge-Petruska and Orgel) has remained 
unclear.  
 
5.3.1 AFM Measurements on Self-Assembled Type I Collagen Microribbons on Mica 
In order to gain a greater understanding of the structural origin of D-banding we explored 
AFM imaging of self-assembled rat tail Type I collagen on mica in order to look at the transition 
between microfibril42 and fibril structures.17,43 The structures formed in this fashion are best 
described as collagen microribbons,11,12 as opposed to the cylindrical fibrils found in nature; 
however, the microribbons do exhibit the same D-spacing pattern. Samples for imaging were 
generated following the general approach of Leow et al. employing collagen molecules from rat-
tail tendon suspended in phosphate buffer.43 The collagen in buffer was incubated on a freshly 
cleaved mica surface followed by rapid wicking away of the buffer solution. Images were obtained 
using either nominal 10 nm conical silicon tips or nominal 1 nm CNT tips. 
A region of self-assembled collagen on mica illustrating the presence of microfibril and 
fibril microribbons is illustrated in Figures 5.1. Three domains are present in the 10 × 10 m 
region shown in panel A. Domain I consists primarily of microfibrils with widths of ~20-40 nm 
and heights of 0.3 to 2 nm. Domain II consists of fibril microribbons that are ~50-60 nm wide and 
~2-3 nm in height. Domain III highlights a micron-sized region where the Domain II fibril 
microribbons come apart into microfibrils and then reassemble. Line profiles of the fibril and 
microfibril microribbons are provided in panels D and E. Metrical parameters from multiple 
measurements of fibrils and microfibrils are summarized in Table 5.1. A previous study by 
Raspanti et al. highlighted similar fibril (Domain II) to microfibril (Domain I) transition by 
electron microscopy.44 
The field of microfibril microribbons illustrated in Domain I of Figures 5.1a and 5.1b can 
be grouped roughly into two sizes. Microfibril bundle A (mfA) (the smallest individual features 
observed in panel b) has an average height of 0.5  0.2 nm, width of 44  13 nm, and cross-
sectional area of 11  5 nm2. Assuming a cross-sectional area of about 1.46 nm2 for a collagen 
molecule, this corresponds to 8  4 collagen molecules per mfA. This corresponds well with the 
average number of five collagen molecules per microfibril bundle obtained from X-ray 
 62 
 
diffraction.5,6,13-15 About five mfA can be seen to merge to form larger microfibril bundles in 
Domain I, assigned as mfB, which have an average height of 1.6  0.3 nm, width of 70  10 nm, 
and cross-sectional area of 58  16 nm2. This area corresponds to 40  11 nm collagen molecules 
per mfB tape. Neither mfA nor mfB exhibit the classic axial periodicity of Type I collagen fibrils 
and they exhibit dramatically shorter persistence lengths of < 60 nm and < 400 nm, respectively. 
The lack of axial periodicity for both mfA and mfB is interesting because AFM is particularly 
sensitive to measuring changes in height with an ability to discern changes on the order of tenths 
of a nanometer. It is possible that the collagen molecules are already ordering with the gap/overlap 
structure and we are unable to detect the overall impact on topography. Alternatively, given the 
high degree of sensitivity of AFM towards this topographical feature, this data suggests that these 
self-assembled microfibrils of < ~40 collagen molecules have not reached the critical size needed 
to generate the higher-order gap/overlap structure. A requirement for a critical number of 
microfibrils is consistent with the proposal of Bozec et al. that rope structures consisting of 
microfibrils are responsible for the axial spacings observed by AFM.45 The rope model does 
provide a ready explanation for axial D-spacing variation.        
The field of fibril microribbons illustrated in Domain II of Figures 5.1a and 5.1b, defined 
as fibril bundle C (fC) are clearly made up of microfibrils from Domain I and consist of many mfA 
and mfB. The fC have an average height of 2.5  0.2 nm, width of 96  11 nm, cross-sectional 
area of 134  15 nm2, and average number of collagen molecules of 92  10. The fC exhibit a 
distinct axial periodicity reminiscent of the D-spacing observed for collagen fibrils in tissue (Panel 
E). Multiple measurements using 2D-FFTs at multiple locations in Domain II gave a D-spacing 
value of 72  29 nm. The disorder present in these microribbons appears to give a large variation 
in the topographical spacing measured. These data indicate that ~90 collagen molecules in cross-
section are sufficient to generate the classic axial periodicity of collagen fibrils. In addition, these 
larger microribbons now exhibit a persistence length of up to 8000 nm.   
Panel C highlights Domain III where mfA can be seen crossing between two different fC 
(yellow ellipses). The cross-links between fC are shorter than a single collagen molecule and 
demonstrating a potential form of fibril-fibril cross-linking based on collagen molecule packing as 
opposed to chemical modification of amino acids. Interestingly, the mfA of collagen molecules 
accomplishes the cross-linking with no apparent disruption to the nanoscale structure, including 
axial periodicity, of the fC. In addition, fC can be seen breaking up into regions of mfbB. In this 
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region, mfB interconnect between multiple fbC sources and ultimately reconnect into new set of 
fC. Panels B and C also highlight a number of fibril microribbons of ~80 nm width that 
interconnect between larger microribbons ~120 nm width while maintaining the D-periodic 
registration with both of the larger fibrils. The fibril structures also provide an interesting cross-
linking mechanism independent of chemical modification and highly conserved in terms of 
maintaining the axial periodicity of the fibril field. 
In order to get a better understanding of the microfibril structure within the fibril 
microribbons (fC) we employed a carbon nanotube (CNT) modified cantilever. These tips have a 
nominal 1 nm diameter with the potential for a perfectly symmetrical tip shape. Collagen fibril 
microribbons imaged in this fashion are illustrated in Figure 5.2 with metrical parameters 
summarized in Table 5.1. The parameters for the microfibrils were obtained by measuring 
individual microfibrils present at the frayed ends of the larger fibril microribbons. These 
microfibrils have an average height of 0.6  0.2 nm, width of 32  6 nm, a cross-sectional area of 
10  4 nm2, and an average number of collagen molecules of 7  3. This somewhat smaller set of 
values may result from a change in tip convolution between the ~10 nm and ~1 nm diameter tip. 
These fibrils, within error the same size as those in Figure 5.1, were also classified as microfibril 
A (mfA). Again, no axial periodicity was observed for these fibrils in isolation; however, as they 
aggregate into the large microribbons shown in Figure 5.2 a very clear axial repeat pattern can be 
observed. The axial spacings show a wide range of values with median of ~80 nm as determined 
by line scans and an average of ~70 nm as determined by 2D-FFTs. There is no systematic 
evidence of the collagen sub-band spacings of ~25, ~23 and ~18 nm in these images. The larger 
microribbons in Figure 5.2 (fibril E, fE) have an average height of 1.5  0.3 nm, width of 240  
40 nm, a cross-sectional area of 200  75 nm2, and an average number of collagen molecules of 
140  50. The center-to-center distance between the microfibrils show regular values of ~24 and 
~32 nm.  
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Figure 5.1 AFM Images of Microfibril and Fibril Domains in Self-Assembled Type I Collagen 
Microribbons on Mica (~10 nm nominal diameter probe). A) Three domains in a 10 x 10 m 
image: I) microfibrils exhibiting short persistence length and no axial repeat spacing II) fibrils 
exhibiting >> 1 m persistence length and the formation of an axial nanoscale repeat structure III) 
fibril/microfibril/fibril transition region. B) Enlargement of the border between Domains I and II 
where fibrils convert into microfibrils. C) Enlargement of domain III highlighting line scans 
employed for quantitative analysis. Yellow ellipses highlight regions were microfibrils cross-
between adjacent fibrils. D) Widths and heights of collagen microribbons from panel C.  
Microribbons 1, 2, and 3 were 47 (1.8), 78 (2.3), and 126 (2.5) nm. E) The axial D-spacing of line 
scans microribbons 4, 5, 6, and 7. The average D-spacing obtained for domain II in Panel A was 
72 (± 29). The nm/pixel ratios are 19.5 in Panel A and 2.0 in Panels B and C. 
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Probe Type Tape 
FWHM 
(nm) 
Tape 
Height 
(nm) 
Tape 
Width 
(nm) 
Tape Cross-
sectional 
Area (nm2) 
Number of 
collagen 
molecules 
Silicon 10 nm radius tip      
Microfibril A 20 (4) 0.5 (0.2) 40 (13) 11  (5) 8 (4) 
Microfibril B 40 (8) 1.6 (0.3) 70 (10) 60 (15) 40 (10) 
Fibril C 60 (7) 2.5 (0.2) 100 (10) 134 (15) 90 (10) 
CNT 1 nm radius tip      
Microfibril A 20 (4) 0.6 (0.2) 32 (6) 10 (4) 7 (3) 
Fibril E 160 (40) 1.5 (0.3) 240 (4) 200 (75) 140 (50) 
 
Table 5.1 Quantitative Analysis of Self-Assembled Type I Collagen Microfibril Microribbons on 
Mica. Microfibril bundle A, the smallest fibrils observed in the images, exhibit a smooth 
morphology devoid of nanoscale substructure including axial D-spacing. Microfibril B is a larger 
sized microfibril bundle apparent in the images that also lacks additional nanoscale substructure. 
Fibril C exhibits nanoscale substructure including a regular axial pattern. The silicon 10 nm radius 
tip data were measured on Figure 5.1. The CNT 1 nm radius tip data were measured on Figure 
5.2.    
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Figure 5.2 AFM Image of Fibril Domains in Self-Assembled Type I Collagen Microribbons on 
Mica (~1 nm nominal diameter CNT probe).  Microfibrils are apparent in the fibril structure in 
additional to a regular axial repeat spacing that ranges from 50-80 nm as measured using 2D-FFTs. 
The microfibrils appear packed next to each other with the smallest center-to-center separations 
showing regular values of ~24 and 32 nm.  Based on fibril width (~20-30 nm) and height (~0.5 
nm) the individual microfibrils observed in this image are consistent with the microfibril bundle 
A structures. 
 
5.4 Conclusions 
Consistent with the proposals from previous structural models,5,6,13-15 microfibrils were 
measured with cross-sectional areas consistent with the presence of five collagen molecules. These 
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smallest microfibrils, as well as larger fibrils consisting of ~5-8 of these microfibrils or about 40 
collagen molecules in cross-section, did not exhibit detectable axial spacings or a substantial 
persistence length. By way of contrast, when the fibrils contained greater than 10 microfibrils and 
about 90 collagen molecules in cross-section, both axial spacing and micron scale persistence 
length were detected. These studies of self-assembled microfibril tapes on mica suggest there may 
be size threshold required before collagen microfibrils attain the persistence length and nanoscale 
morphology, as characterized by axial D-spacing, that is characteristic of collagen fibrils. The 
presence of the mica surface is a substantial perturbation43 and additional efforts are required to 
understand the relationship of this size threshold to tissue self-assembly. 
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Chapter 6  
Conclusions and Future Outlook 
 
6.1 Summary of Key Findings 
6.1.1 Estrogen Depletion and Drug Treatments Alter Nano and Microstructure at Multiple 
Hierarchical Levels 
 The structure of type I collagen was assessed at multiple hierarchical levels. The 
nanostructure was studied at the level of D-spacing and microstructure was studied at the level of 
individual fibrils as well as fibril alignment over a 3.5 µm2 area. The effect of estrogen depletion 
and drug treatment was dependent on the hierarchical level being considered. D-spacing was only 
altered for fibrils in bundles in trabecular bone. In this case, the drug treatment groups exhibited 
statistically significant animal-to-animal variability in the D-spacing. Individual fibrils and their 
association with bundles or sheets was described in chapters 21 and 32 using the Parallel/Oblique 
hand-coding method. In this analysis, estrogen depletion and drug treatment only altered cortical 
bone. The trabecular bone was altered at the larger scale analysis using a fibril alignment parameter 
(FAP), Chapter 3.2 
 The work reported in Chapters 2 and 3 is unique from other work in this field. There were 
a total of 84 animals across five different treatment groups and 8,032 individual collagen fibrils 
measured. This is a much larger sample size relative to similar studies in the literature.3 
Additionally, there is a full and independent biological replicate in Chapter 2. 
 
6.1.2 Pigment Epithelium Derived Factor Binds Heterogeneously in Rabbit Femur 
 Pigment epithelium derived factor (PEDF) was conjugated to 10 nm gold nanoparticles 
through a streptavidin/streptavidin-tag system. The gold nanoparticles were detected with phase 
images from tapping mode AFM as well as combined AFM-IR. Gold is harder than collagen and 
is expected to have a different phase lag than collagen in the phase image when imaging in tapping 
mode. The phase contrast of the phase images provided evidence that PEDF interacts with collagen 
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at the interfaces of bundles and sheets and not within the bundles or sheets. Additionally, in areas 
of high fibril disorder, PEDF interactions were observed along fibril edges and not on top of the 
fibrils. These observations suggest that PEDF binds heterogeneously in rabbit femur. 
 
6.1.3 Type I Collagen Nanomorphology 
 Collagen molecules were self-assembled into collagen microfibrils and fibril tapes on mica 
and imaged with AFM. Imaging included the transition between microfibrils and fibril tapes as 
well as high resolution images of microfibrils within a fibril using a Carbon Nanotube tip that had 
a diameter of ~1 nm. Measurements of height, width, and D-spacing (when present) revealed that 
there is a size threshold that must be reached before a fibril has the persistence length to have a D-
spacing. This threshold is estimated to be about 10 microfibrils or 90 collagen molecules in cross-
section. 
 These conclusions are inconsistent with published models for the origin of D-spacing.4,5 
The Hodge-Petruska model proposes as two-dimensional stacking of collagen microfibrils in a 
regular pattern to produce one value for D-spacing (67 nm).4 The Orgel model for the origin of D-
spacing is an extension of the Hodge-Petruska model in three dimensions. This model requires 
collagen to be crystalline and only have one possible value for D-spacing. Additionally, D-spacing 
is present at the level of microfibrils in this model.5 Chapter 5 presents data that is not consistent 
with these models. The Hodge-Petruska and Orgel models need to be refined in order to explain a 
distribution of D-spacings as well as a critical threshold of collagen microfibrils that must be 
reached before D-spacing is observed.  
 
6.2 Future Directions 
6.2.1 Detecting endogenous PEDF in rabbit femur 
 In Chapter 4, PEDF binding sites were detected using gold nanoparticles as a secondary 
tag and detecting the gold nanoparticles with AFM phase imaging and IR. However, it is unclear 
if the observed binding sites represent all PEDF binding sites or if they represent sites where PEDF 
can bind but didn’t bind in the animal. These two possibilities are outlined in Figure 6.1. If there 
is no endogenous PEDF remaining on the sample, then the PEDF-Au nanoparticles are able to 
bind to any PEDF binding site on the bone surface (Figure 6.1a). As shown in Figure 6.1b, if 
endogenous PEDF is still present in the sample, then those binding sites would not be available 
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for binding with exogenous PEDF (containing the gold nanoparticles). In this case, any gold 
nanoparticles detected with AFM would represent sites on the bone surface that are available for 
PEDF binding but were not bound by PEDF in the animal. 
 
 
Figure 6.1 a) The freshly prepared (untreated) rabbit femur does not contain any endogenous 
PEDF from the animal. Upon exposure to exogenous PEDF (via PEDF-Au nanoparticles) using 
Scheme 4.1 of Scheme 4.2 (Chapter 4), PEDF will bind to any possible PEDF binding site on the 
surface of the femur sample. b) The freshly prepared (untreated) rabbit femur contains endogenous 
PEDF from the animal. These PEDF binding sites are not available for binding by exogenous 
PEDF. Scheme 4.1 of Scheme 4.2 will produce a sample in which the exogenous PEDF (PEDF-
Au nanoparticles) binds to the femur surface at sites where PEDF can bind but didn’t bind in the 
animal. 
 
In order to test this, endogenous PEDF on the untreated femur samples will be stained and 
then detected by AFM phase imaging and IR. The procedures and possible outcomes are outlined 
in Figure 6.2. First, a freshly prepared rabbit femur will be exposed to a primary antibody (anti-
PEDF antibody, Abcam ab14993, IgG, polyclonal). Then, the sample will be exposed to a 
secondary antibody (Goat Anti-Rabbit IgG, Abcam ab6720) that reacts with the primary antibody 
and is conjugated to biotin. The streptavidin protein binds with high affinity to biotin and can be 
used to attach a tag with gold nanoparticles. The same streptavidin-gold nanoparticles used in 
Chapter 4 (Schemes 4.1, 4.2, and 4.3) will be used tag the secondary antibody. The gold 
nanoparticles will be detected using the same methods discussed in Chapter 4 (AFM phase imaging 
and AFM-IR). In the absence of endogenous PEDF, all antibodies and the streptavidin-Au 
nanoparticles will be washed away with buffer (Figure 6.2a). In the presence of endogenous 
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PEDF, the antibodies and streptavidin-Au nanoparticles will stain the surface at endogenous PEDF 
binding sites. In this case, it is expected that AFM phase imaging and AFM-IR would detect the 
presence of the gold nanoparticles (Figure 6.2b).  
 
 
Figure 6.2 Endogenous PEDF will be detected using antibodies and streptavidin-Au nanoparticles. 
The primary antibody will be an antibody for rabbit PEDF. The secondary antibody will be a 
polyclonal IgG antibody that reacts with the primary antibody and is tagged with biotin. 
Streptavidin-Au will bind to biotin. a) Without endogenous PEDF, staining with antibodies and 
streptavidin-Au will result in a surface without gold nanoparticles on the surface. b) In the presence 
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of endogenous PEDF, staining with antibodies and streptavidin-Au will result in a surface with a 
gold nanoparticle at sites where endogenous PEDF is bound to the surface of the femur sample. 
In Chapter 4, PEDF binding was heterogenous in rabbit femur. Due to this heterogeneity 
of binding and the heterogeneity of bone, it will be important to image many locations. Initial AFM 
scans are 10 x 10 µm and the polished surface of the femur is 1 cm x 0.75 cm on average. One 10 
x 10 µm scan is only 0.00013% of the total polished surface available for imaging. If gold 
nanoparticles are present (there is endogenous PEDF), imaging many locations will increase the 
probability of randomly choosing a location with gold nanoparticles. The absence of gold 
nanoparticles in the AFM image could be attributed to the lack of endogenous PEDF or imaging a 
location that does not contain endogenous PEDF even if it is present elsewhere on the sample. In 
Chapter 2, six imaging locations were required to obtain data that was representative of the entire 
sample.1 Imaging in a similar manner (six locations distributed evenly across the sample) should 
result in the detection of endogenous PEDF if it is present. 
 
6.2.2 Comparing PEDF Binding Sites to Type I Collagen Microstructure 
Chapter 3 described an automated image analysis that generated a fibril alignment 
parameter and associated heat map.2 The heat maps provide a color scale that indicate areas or 
high collagen fibril alignment and low fibril alignment on an image. Using this analysis for the 
images of PEDF bound to bone could potentially allow us to observe relationships between 
collagen microstructure and PEDF binding events. The heat map could be overlaid on top of an 
image that showed gold nanoparticles. If the nanoparticles bind preferentially at certain areas of 
the color scale, this would be additional evidence that PEDF binding is heterogeneous in bone. 
 
6.2.3 Detecting PEDF Binding Sites in Self-Assembled Collagen 
 Imaging locations of PEDF binding on self-assembled collagen microfibrils and fibrils will 
provide information to help explain the heterogeneity of binding observed in Chapter 4. In Figure 
6.3, self-assembled collagen on mica from a 25 µg/mL collagen solution was exposed to 0.4 nM 
PEDF and 0.4 nM streptavidin-Au using Scheme 4.1. The microfibrils and fibril tapes on mica are 
small enough that the gold nanoparticles can be detected by height in the topography AFM image. 
For this sample, collagen microfibrils and fibril tapes were 2-5 nm in height (Figure 6.3a). Upon 
exposure to PEDF and streptavidin-Au, features with heights of 6-10 nm were present (Figure 
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6.3b). These features are likely the gold nanoparticles but the sample needs to be measured with 
AFM-IR to confirm the identity of the particles. Figure 6.3c displays a line scan along the fibril 
axis. The height of the particle is 7 nm with respect to the fibril. Height variation along the fibril 
due to D-spacing is much smaller than 7 nm. The PEDF/streptavidin-Au nanoparticles interact 
with the collagen fibril along the fibril axis (Figure 6.3d). Areas of the fibril tape without binding 
can be detected between the particles and this indicates that individual binding events are being 
detected. 
The presence of the gold nanoparticles indicate that PEDF binding can occur in the absence 
of post-translational modifications that would occur in the animal. Additionally, there were no 
binding events observed between the nanoparticles and microfibrils. In Chapter 5, D-spacing was 
not observed in microfibrils but was observed for fibrils with greater than 90 collagen molecules. 
PEDF is a collagen chaperone protein and its inability to bind to microfibrils could be a 
biochemical explanation for the lack of D-spacing in microfibrils.  
For this self-assembled sample, PEDF binding was detected along the fibril. This is 
inconsistent with binding observed in tissue (Chapter 4). PEDF finding is not observed on all fibril 
tapes or along an entire fibril. It is unclear if PEDF binds heterogeneously to a single fibril or if 
the PEDF/streptavidin-Au concentration was too low to observe all binding sites that are present. 
This experiment needs to be repeated at multiple concentrations of PEDF/streptavidin-Au to make 
the assessment. This type of experiment will provide information about the source of 
heterogeneous binding seen in tissue (Chapter 4). If PEDF binds homogenously along a fibril, then 
the heterogeneity of binding observed in bone is due to the heterogeneity of collagen 
microstructures. If PEDF binding is heterogeneous along the fibril, this could potentially explain 
the pattern of binding seen in bone.  
I hypothesize that the heterogeneity seen in bone is both at the fibril level and at the level 
of microstructure. PEDF/collagen binding is sequence dependent6,7 which explains heterogeneous 
binding along the fibril. Binding was not observed at areas of high collagen alignment in Chapter 
4. Thus, the binding of PEDF in tissue is likely heterogeneous at both the fibril and microstructure 
level.  
 78 
 
  
Figure 6.3 PEDF binding in self assembled microfibrils and fibril tapes. a) Self assembled 
collagen without exposure to PEDF, b) After exposure to PEDF, binding was detected along the 
axis of fibril tapes but not on microfibrils, c) Line scan along a fibril tape with one binding event 
detected, d) Individual binding events are detected along the fibril tape. 
 
6.2.4 Nano and Micro Structural Changes with OI Type VI 
Binding of pigment epithelium derived factor (PEDF) is dependent upon the microstructure 
of type I collagen in bone (Chapter 4). A loss of function mutation in the gene encoding PEDF 
results in osteogenesis imperfecta (OI) type VI8,9 with a nano and microstructural defect in bone 
mineralization patterns.10 Work still needs to be done to determine if collagen nano and 
microstructural changes are occurring with OI type VI. This is a likely hypothesis because 
mineralization occurs after collagen has been synthesized and the collagen fibrils template mineral 
formation. 
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The combined AFM-IR technique could potentially be useful in these experiments. The 
mineral component of bone also has a strong absorbance in the IR spectra. This technique has also 
been used to assess the mineral content (1030/1660 cm-1) and crystallinity (1030/1020 cm-1) of 
bone as well as the acid phosphate content (1128/1096 cm-1).11 This technique can be used to study 
the role of mineral in collagen microstructure. 
 
6.2.5 Relating Nano and Microstructure Changes to Bone Remodeling Rates 
In Chapters 2 and 3, the microstructure of type I collagen in bone was altered by estrogen 
depletion and drug treatment. The biochemical process that leads to various collagen 
microstructures is unknown but collagen microstructure must be determined during collagen 
synthesis (bone remodeling) or after synthesis (post-translational modifications). Bone remodeling 
rates for both cortical femur and trabecular lumbar vertebrae have been measured for the animals 
used throughout this thesis.12 In this animal study, estrogen depletion resulted in cortical and 
trabecular bone loss. Treatment with either ALN or CatKI prevented OVX induced bone loss in 
both cases, demonstrating that both drugs are effective antiresorptives. Additionally, there was an 
increase in the bone formation rate with OVX treatment in both cortical and trabecular bone. OVX 
+ ALN and OVX + ERT treated animals had bone formation rates that were not different from the 
Sham animals. This suggests that ALN and ERT cause a decrease in bone resorption and bone 
formation. Treatment with CatKI had no effect on bone formation rates in either cortical or 
trabecular bone. Bone resorption and formation are uncoupled under CatKI treatment.12 
  Due to the altered rates of bone formation, I hypothesize that microstructure is determined 
as the osteoblast is forming new bone during remodeling. Additional work is needed to test this 
hypothesis. One method could be to tag bone as it is being formed in the animal. Comparing 
collagen microstructure at sites of bone formation at the same point in time after OVX surgery (or 
Sham surgery) would provide information on how collagen microstructure is being altered with 
remodeling.  
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Figure A.1 Summary of sample treatment prior or imaging, imaging locations, and sampling with 
each location. 
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Approximately 1.0 cm of rabbit femur mid-diaphysis was sectioned and mounted onto an 
AFM puck (Figure A.1b). The sample area of 1.0 × 0.75 cm was polished 100-300 m below the 
bone surface and demineralized for 90 minutes using EDTA. All images were acquired in the plane 
parallel to the long bone axis. No variation in collagen structure was noted as a function of the 
polishing depth employed. Image acquisition for the mid-diaphysis sections proceeded using the 
follow procedure. First, 30 × 30 m scans were obtained in six regions of the 1.0 × 0.75 cm bone 
imaging area (Figure A.1c). These were followed by 10 × 10 m scans and finally the 3.5 × 3.5 
m scans employed for image analysis (Figure A.1d). This approach ensured that the nano to 
micro scale analysis of collagen fibrils was distributed across the 0.75 × 1.0 cm imaging area. An 
average of six 30 × 30 m scans and thirteen 3.5 × 3.5 m scans were obtained per animal. From 
these regions, the average of 75 fibrils per animal was obtained around which the Parallel and 
Oblique microstructures were observed. 
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Figure A.2 Representative images of additional microarchitectures coded in both Data Sets I and 
II: a) fibril pair; b) fibril across bundle or sheet. 
 
 
 
 
 
 
 
 
a) 
b) 
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Statistical Analysis 
D-spacing analysis employed a linear mixed ANOVA model with a random effect per 
animal and per index (bundles and sheets i.e. Parallel microstructure and Oblique microstructure). 
Mean D-spacings for fibrils in bundles were determined as a function of treatment group and were 
found to be 63.6, 64.0, 63.2, and 63.1 nm for Sham, OVX, OVX + ALN, and OVX + CatKI 
respectively with standard error of 0.4. These differences were not significant and had Tukey-
Kramer adjusted p-values of >0.50. Mean D-spacings for fibrils in sheets were determined as a 
function of treatment group and were found to be 62.6, 63.9, 63.6, and 62.7 nm for Sham, OVX, 
OVX + ALN, and OVX + CatKI respectively with standard error of 0.4. These differences were 
not significant and had Tukey-Kramer adjusted p-values of >0.12. Thus, neither the sub-regions 
of the Parallel microstructure, nor the sum of the fibril sets, exhibited significant shifts in the D-
spacing value. The largest variance arose from the between fibril differences within an animal that 
was 7.4 nm for bundles and 3.8 nm for sheets. Plots of the D-spacing distributions are illustrated 
in Figure A.3. Previous studies of Sham and OVX sheep noted a treatment dependent shift in D-
spacing distribution.1, 2 No changes in D-spacing distributions are noted for the studies of Sham, 
OVX, and drug treated rabbits.  
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Figure A.3 D-spacing distributions for cortical bone from the mid-diaphysis of the rabbit femur. 
a) Histogram of D-spacing values for Sham, OVX, OVX + ALN, and OVX + CatKI (Data Set I), 
b) Cumulative density function of D-spacing values for Sham, OVX, OVX + ALN, and OVX + 
CatKI (Data Set I), c) Histogram of D-spacing values for Sham, OVX, and OVX + ERT (Data Set 
II), d) Cumulative density function of D-spacing values for Sham, OVX, and OVX + ERT (Data 
Set II). 
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Figure A.4 Representative images from the Sham, OVX, OVX + ALN, OVX + CatKI, and OVX 
+ ERT data sets. 
Figure A.4.1 Sham animals in Data Set I (i and ii) and Data Set II (iii and iv). 
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Figure A.4.2 OVX animals in Data Set I (i and ii) and Data Set II (iii and iv). 
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Figure A.4.3 OVX + ALN animals in Data Set I. 
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Figure A.4.4 OVX + CatKI animals in Data Set I. 
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Figure A.4.5 OVX + ERT animals in Data Set II. 
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Appendix B 
Estrogen Depletion and Drug Treatment Alters the Microstructure of Type I 
Collagen in Bone 
In collaboration with Matt Muckley, Dr. Ming Fang, Prof. Jeffrey A. Fessler, Dr. Kathleen 
Welch, Prof. Edward D. Rothman, Prof. Bradford G. Orr, Dr. Le T. Duong, and Prof. Mark M. 
Banaszak Holl  
 
 
Figure B.1 Rabbit femur and lumbar vertebrae a) A section of rabbit femur was taken from the 
mid-diaphysis and mounted onto a steel puck. The remaining femur is shown behind the mounted 
sample. The mounted sample has been demarrowed, polished, and demineralized. b) The rabbit 
lumbar vertebrae sections were taken from the caudal end of the vertebrae. The mounted sample 
pictured has been demarrowed, polished, and demineralized. 
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Figure B.2 Summary of D-spacing distributions in rabbit lumbar vertebrae.  a) Histogram of all 
D-spacings measured for trabecular lumbar vertebrae, b) Boxplots of all D-spacings measured for 
trabecular lumbar vertebrae, c) Cumulative density function (CDF) of all D-spacings measured for 
trabecular lumbar vertebrae. There is not a significant difference between the average D-spacing 
values or the distribution of all D-spacing values as assessed by the Kolmorgorov-Smirnov statistic 
of the CDF.      
 
a) 
b) c) 
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Figure B.3 Image of collagen, with arrows showing local alignment of collagen patches. The 
alignment was determined using an autocorrelation-based method. The arrow lengths are scaled to 
show the degree of alignment. 
 
 
 
Figure B.4 Image of collagen, with arrows showing local alignment of collagen patches. The 
alignment was determined using an autocorrelation-based method. The arrow lengths are scaled to 
show the degree of alignment. 
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Figure B.5 Exemplary images of Sham rabbit cortical femur that correspond with Figure 3.4b 
with the superimposed vector fields and heat maps. The values included with each image are the 
fibril alignment parameter values. 
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Figure B.6 Exemplary images of Sham rabbit trabecular lumbar vertebrae (lv) that correspond 
with Figure 3.4b with the superimposed vector fields and heat maps. The values included with 
each image are the fibril alignment parameter values. 
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Figure B.7 Representative outputs from the autocorrelation-based analysis of AFM images from 
cortical femur samples. The left panel contains the amplitude AFM images with the superimposed 
vector fields. The arrows were calculated using the autocorrelation-based method (see Figures B.3 
and B.4). The right panel contains the corresponding heat maps. The heat maps show the alignment 
between a given vector with the vectors surrounding it. The images shown have approximately the 
same fibril alignment parameter (FAP) but come from different treatment groups.  a-b) Sham, FAP 
= 0.8; c-d) OVX, FAP = 0.7; e-f) OVX + ALN, FAP = 0.9; and g-h) OVX + CatKI, FAP = 0.9. 
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Figure B.8 Representative outputs from the autocorrelation-based analysis of AFM images from 
trabecular lumbar vertebrae samples. The left panel contains the amplitude AFM images with the 
superimposed vector fields. The arrows were calculated using the autocorrelation-based method 
(see Figures B.3 and B.4). The right panel contains the corresponding heat maps. The heat maps 
show the alignment between a given vector with the vectors surrounding it. All images shown have 
a fibril alignment parameter (FAP) of 0.9 but come from different treatment groups.  a-b) Sham, 
c-d) OVX, e-f) OVX + ALN, and g-h) OVX + CatKI. 
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Figure B.9 Cumulative density function plots of FAP values to show the difference between 
cortical femur and trabecular lumbar vertebrae (lv) for each of the four treatment groups. For all 
plots, the average FAP value is the same for cortical and trabecular samples. a) The distribution of 
FAP values for Sham cortical femur is shifted towards lower values (more aligned collagen) in 
comparison to Sham trabecular lumbar vertebrae. b) Estrogen depletion resulted in cortical femur 
and trabecular lumbar vertebrae producing the same average and the same distribution of FAP 
values. The similarity in the distribution of FAP values arises from estrogen depletion shifting 
trabecular lumbar vertebrae towards lower FAP values while not affecting the cortical femur FAP 
values (Figure 3.6). OVX is the only treatment group with this result. c) OVX + ALN shifted 
cortical femur towards lower FAP values and trabecular lumbar vertebrae towards higher FAP 
values (Figure 3.6). As a result, cortical femur has a distribution of FAP values that are lower than 
trabecular lumbar vertebrae but the distributions are farther apart than Sham. d) OVX + CatKI 
cortical femur also has a distribution of FAP values that is shifted towards lower values. 
